Polymer coatings containing drug powder of controlled morphology

ABSTRACT

A method for depositing a coating comprising a polymer and pharmaceutical agent on a substrate, comprising the following steps: discharging at least one pharmaceutical agent in a therapeutically desirable morphology in dry powder form through a first orifice; discharging at least one polymer in dry powder form through a second orifice; depositing the polymer and/or pharmaceutical particles onto said substrate, wherein an electrical potential is maintained between the substrate and the pharmaceutical and/or polymer particles, thereby forming said coating; and sintering said coating under conditions that do not substantially modify the morphology of said pharmaceutical agent.

CROSS-REFERENCE

This application claims the benefit of U.S. Provisional Application Nos.60/699,650 filed Jul. 15, 2005; 60/752,338 filed Dec. 20, 2005;60/771,066 filed Feb. 7, 2006; 60/771,725 filed Feb. 8, 2006; 60/745,731filed Apr. 26, 2006; and 60/745,733 filed Apr. 26, 2006 which areincorporated herein by reference in its entirety.

BACKGROUND OF THE INVENTION

The present invention relates to methods for depositing a coatingcomprising a polymer and a pharmaceutical or biological agent in powderform onto a substrate.

It is often beneficial to provide coatings onto substrates, such thatthe surfaces of such substrates have desired properties or effects.

For example, it is useful to coat biomedical implants to provide for thelocalized delivery of pharmaceutical or biological agents to targetspecific locations within the body, for therapeutic or prophylacticbenefit. One area of particular interest is drug eluting stents (DES)that has recently been reviewed by Ong and Serruys in Nat. Clin. Pract.Cardiovasc. Med., (December 2005), Vol 2, No 12, 647. Typically suchpharmaceutical or biological agents are co-deposited with a polymer.Such localized delivery of these agents avoids the problems of systemicadministration, which may be accompanied by unwanted effects on otherparts of the body, or because administration to the afflicted body partrequires a high concentration of pharmaceutical or biological agent thatmay not be achievable by systemic administration. The coating mayprovide for controlled release, including long-term or sustainedrelease, of a pharmaceutical or biological agent. Additionally,biomedical implants may be coated with materials to provide beneficialsurface properties, such as enhanced biocompatibility or lubriciousness.

Conventionally, coatings have been applied by processes such as dipping,spraying, vapor deposition, plasma polymerization, andelectro-deposition. Although these processes have been used to producesatisfactory coatings, there are drawbacks associated therewith. Forexample it is often difficult to achieve coatings of uniform thicknessesand prevent the occurrence of defects (e.g. bare spots). Also, in manyprocesses, multiple coating steps are frequently necessary, usuallyrequiring drying between or after the coating steps.

Another disadvantage of most conventional methods is that manypharmaceutical or biological agents, once deposited onto a substrate,suffer from poor bioavailability, reduced shelf life, low in vivostability or uncontrollable elution rates, often attributable to poorcontrol of the morphology and/or secondary structure of the agent.Pharmaceutical agents present significant morphology control challengesusing existing spray coating techniques, which conventionally involve asolution containing the pharmaceutical agents being spayed onto asubstrate. As the solvent evaporates the agents are typically left in anamorphous state. Lack of or low degree of crystallinity of the spraycoated agent can lead to decreased shelf life and too rapid drugelution. Biological agents typically rely, at least in part, on theirsecondary, tertiary and/or quaternary structures for their activity.While the use of conventional solvent-based spray coating techniques maysuccessfully result in the deposition of a biological agent upon asubstrate, it will often result in the loss of at least some of thesecondary, tertiary and/or quaternary structure of the agent andtherefore a corresponding loss in activity. For example, many proteinslose activity when formulated in carrier matrices as a result of theprocessing methods.

Conventional solvent-based spray coating processes are also hampered byinefficiencies related to collection of the coating constituents ontothe substrate and the consistency of the final coating. As the size ofthe substrate decreases, and as the mechanical complexity increases, itgrows increasingly difficult to uniformly coat all surfaces of asubstrate.

What is needed is a cost-effective method for depositing inert polymersand pharmaceutical or biological agents onto a substrate, where thecollection process is efficient, the coating produced is conformal,substantially defect-free and uniform, the composition of the coatingcan be regulated and the morphology and/or secondary structure of thepharmaceutical or biological agents can be controlled. The method wouldthus permit structural and morphological preservation of the agentsdeposited during the coating process.

SUMMARY OF THE INVENTION

In one aspect, the invention provides a coated coronary stent,comprising: a stent framework; and a rapamycin-polymer coating whereinat least part of rapamycin is in crystalline form.

In another aspect, the invention provides a coated coronary stent,comprising: a stent framework; and a macrolide immunosuppressive (limus)drug-polymer coating wherein at least part of the drug is in crystallineform. In one embodiment, the macrolide immunosuppressive drug comprisesone or more of rapamycin, 40-O-(2-Hydroxyethyl)rapamycin (everolimus),40-O-Benzyl-rapamycin, 40-O-(4′-Hydroxymethyl)benzyl-rapamycin,40-O-[4′-(1,2-Dihydroxyethyl)]benzyl-rapamycin, 40-O-Allyl-rapamycin,40-O-[3′-(2,2-Dimethyl-1,3-dioxolan-4(S)-yl)-prop-2′-en-1′-yl]-rapamycin,(2′:E,4′S)-40-O-(4′,5′-Dihydroxypent-2′-en-1′-yl)-rapamycin40-O-(2-Hydroxy)ethoxycar-bonylmethyl-rapamycin,40-O-(3-Hydroxy)propyl-rapamycin 4O-O-(6-Hydroxy)hexyl-rapamycin40-O-[2-(2-Hydroxy)ethoxy]ethyl-rapamycin4O-O-[(3S)-2,2-Dimethyldioxolan-3-yl]methyl-rapamycin,40-O-[(2S)-2,3-Dihydroxyprop-1-yl]-rapamycin,4O-O-(2-Acetoxy)ethyl-rapamycin 4O-O-(2-Nicotinoyloxy)ethyl-rapamycin,4O-O-[2-(N-Morpholino)acetoxy]ethyl-rapamycin4O-O-(2-N-Imidazolylacetoxy)ethyl-rapamycin,40-O-[2-(N-Methyl-N′-piperazinyl)acetoxy]ethyl-rapamycin,39-O-Desmethyl-39,40-O,O-ethylene-rapamycin,(26R)-26-Dihydro-40-O-(2-hydroxy)ethyl-rapamycin, 28-O-Methyl-rapamycin,4O-O-(2-Aminoethyl)-rapamycin, 4O-O-(2-Acetaminoethyl)-rapamycin4O-O-(2-Nicotinamidoethyl)-rapamycin,4O-O-(2-(N-Methyl-imidazo-2′-ylcarbethoxamido)ethyl)-rapamycin,4O-O-(2-Ethoxycarbonylaminoethyl)-rapamycin,40-O-(2-Tolylsulfonamidoethyl)-rapamycin,40-O-[2-(4′,5′-Dicarboethoxy-1′,2′,3′-triazol-1′-yl)-ethyl]-rapamycin,42-Epi-(tetrazolyl)rapamycin (tacrolimus), and42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin(temsirolimus).

In yet another aspect, the invention provides a method for coating asubstrate, said coating comprising

at least one polymer; and

at least one pharmaceutical agent in a therapeutically desirablemorphology and/or at least one active biological agent;

said method comprising the following steps:

discharging the at least one pharmaceutical agent and/or at least oneactive biological agent in dry powder form through a first orifice;

discharging the at least one polymer in dry powder form through a secondorifice;

depositing the polymer and pharmaceutical agent and/or active biologicalagent particles onto said substrate, wherein an electrical potential ismaintained between the substrate and the polymer and pharmaceuticalagent and/or active biological agent particles, thereby forming saidcoating; and

sintering said coating under conditions that do not substantially modifythe morphology of said pharmaceutical agent and/or the activity of saidbiological agent.

In a further aspect, the invention a method for coating a substrate,said coating comprising

at least one polymer; and

at least one pharmaceutical agent in a therapeutically desirablemorphology and/or at least one active biological agent;

said method comprising the following steps:

discharging the at least one pharmaceutical agent and/or at least oneactive biological agent in dry powder form through a first orifice;

forming a supercritical or near supercritical fluid solution comprisingat least one supercritical fluid solvent and at least one polymer anddischarging said supercritical or near supercritical fluid solutionthrough a second orifice under conditions sufficient to form solidparticles of the polymer;

depositing the polymer and pharmaceutical agent and/or active biologicalagent particles onto said substrate, wherein an electrical potential ismaintained between the substrate and the polymer and pharmaceuticalagent and/or active biological agent particles, thereby forming saidcoating; and

sintering said coating under conditions that do not substantially modifythe morphology of said pharmaceutical agent and/or the activity of saidbiological agent.

A further aspect of the invention provides a method for depositing acoating onto a substrate, said coating comprising

at least one polymer; and

at least one pharmaceutical agent in a therapeutically desirablemorphology in dry powder form and/or at least one active biologicalagent;

said method comprising the following steps:

discharging the at least one pharmaceutical agent and/or at least oneactive biological agent through a first orifice;

forming a first stream of a polymer solution comprising at least onesolvent and at least one polymer;

forming a second stream of a supercritical or near supercritical fluidcomprising at least one supercritical fluid;

contacting said first and second streams, whereby said supercritical ornear supercritical fluid acts as a diluent of said solution underconditions sufficient to form particles of said polymer;

depositing the polymer and pharmaceutical agent and/or active biologicalagent particles onto said substrate, wherein an electrical potential ismaintained between the substrate and the polymer and pharmaceuticalagent and/or active biological agent particles, thereby forming saidcoating; and

sintering said coating under conditions that do not substantially modifythe morphology of said pharmaceutical agent and/or the activity of saidbiological agent.

Yet another aspect of the invention provides a coated implantablemedical device, comprising: a substrate; and

a coating having substantially uniform thickness disposed on saidsubstrate, wherein said coating comprises at least one polymer and atleast one pharmaceutical agent in a therapeutically desirable morphologyand/or at least one active biological agent comprising an activesecondary, tertiary or quaternary structure.

In one embodiment, the device is selected from the group consisting ofstents, joints, screws, rods, pins, plates, staples, shunts, clamps,clips, sutures, suture anchors, electrodes, catheters, leads, grafts,dressings, pacemakers, pacemaker housings, cardioverters, cardioverterhousings, defibrillators, defibrillator housings, prostheses, eardrainage tubes, ophthalmic implants, orthopedic devices, vertebraldisks, bone substitutes, anastomotic devices, perivascular wraps,colostomy bag attachment devices, hemostatic barriers, vascularimplants, vascular supports, tissue adhesives, tissue sealants, tissuescaffolds and intraluminal devices.

A further aspect of the invention provides a method for depositing acoating comprising a polymer and pharmaceutical agent on a substrate,wherein the method comprises the following steps:

forming a first supercritical or near critical fluid mixture thatincludes said at least one pharmaceutical agent;

forming a second supercritical or near critical fluid mixture thatincludes at least one polymer;

discharging the first supercritical or near critical fluid mixturethrough a first orifice under conditions sufficient to form solidparticles of the pharmaceutical agent;

discharging the second supercritical or near critical fluid mixturethrough said first orifice or through a second orifice under conditionssufficient to form solid particles of the polymer;

depositing the solid pharmaceutical particles and/or polymer particlesonto said substrate, wherein an electrical potential is maintainedbetween the substrate and the pharmaceutical and/or polymer particles,thereby forming said coating; and

sintering said coating under conditions that do not substantially modifythe morphology of said solid pharmaceutical particles.

Another aspect provides a method for depositing a coating comprising apolymer and a pharmaceutical agent on a substrate, comprising thefollowing steps;

forming a first stream of a polymer solution comprising a first solventand at least one polymer;

forming a second stream of a supercritical or near critical fluidmixture,

contacting said first and second streams, whereby said supercritical ornear critical fluid acts as a diluent of said first solvent underconditions sufficient to form particles of the polymer;

forming a third stream of a solution comprising a second solvent and atleast one pharmaceutical agent;

forming a fourth stream of a supercritical or near critical fluidmixture,

contacting said third and fourth streams, whereby said supercritical ornear critical fluid acts as a diluent of said second solvent underconditions sufficient to form particles of the pharmaceutical agent;

depositing the polymer and/or pharmaceutical particles onto saidsubstrate, wherein an electrical potential is maintained between thesubstrate and the pharmaceutical and/or polymer particles, therebyforming said coating; and

sintering said coating under conditions that do not substantially modifythe morphology of said solid pharmaceutical particles.

Yet another aspect of the invention provides a method for depositing acoating comprising a polymer and a pharmaceutical agent on a substrate,wherein the substrate is pre-coated with one or more polymers, themethod comprising the following steps;

forming a first stream of a solution comprising a solvent and at leastone pharmaceutical agent;

forming a second stream of a supercritical or near critical fluidmixture,

contacting said first and second streams, whereby said supercritical ornear critical fluid acts as a diluent of said solvent under conditionssufficient to form particles of the pharmaceutical agent;

depositing the pharmaceutical particles onto said substrate, wherein anelectrical potential is maintained between the substrate and thepharmaceutical particles, thereby forming said coating; and

sintering said coating under conditions that do not substantially modifythe morphology of said solid pharmaceutical particles.

A further aspect provides a method for depositing a coating comprising apolymer and a pharmaceutical agent on a substrate, wherein the substrateis pre-coated with one or more pharmaceutical agents, the methodcomprising the following steps;

forming a first stream of a solution comprising a solvent and at leastone polymer; forming a second stream of a supercritical or near criticalfluid mixture,

contacting said first and second streams, whereby said supercritical ornear critical fluid acts as a diluent of said solvent under conditionssufficient to form particles of the polymer;

depositing the polymer particles onto said substrate, wherein anelectrical potential is maintained between the substrate and thepharmaceutical particles, thereby forming said coating; and

sintering said coating under conditions that do not substantially modifythe morphology of said solid pharmaceutical particles.

Yet another aspect of the invention provides a method for depositing acoating comprising a polymer and pharmaceutical agent on a substrate,wherein the method comprises the following steps:

co-introducing into a coaxial cylindrical spray tube an anti-solventfluid mixture which is a supercritical or a near-critical fluid mixtureand a solution or suspension of at least one pharmaceutical agent in avehicle which is soluble or substantially soluble in the anti-solventfluid mixture; contacting the anti-solvent fluid with said solution orsuspension of at least one pharmaceutical agent to form a combinedstream containing the supercritical or a near-critical fluid mixture,the vehicle and the pharmaceutical agent;

spraying the combined stream through an orifice of said tube into avessel, wherein said vehicle is extracted from the solution orsuspension and particles of the pharmaceutical agent substantially freeof the vehicle are formed prior to deposition of said pharmaceuticalparticles on said substrate;

depositing the pharmaceutical particles onto a substrate pre-coated withparticles of at least one polymer disposed into said vessel wherein anelectrical potential is maintained between the substrate and the polymerparticles, thereby forming said coating; and

sintering said coating under conditions that do not substantially modifythe morphology of said solid pharmaceutical particles.

Still further aspect of the invention provides a method for depositing acoating comprising a polymer and pharmaceutical agent on a substrate,wherein the method comprises the following steps:

co-introducing into a coaxial cylindrical spray tube an anti-solventfluid mixture which is a supercritical or a near-critical fluid mixtureand a solution or suspension of at least one polymer in a vehicle whichis soluble or substantially soluble in the anti-solvent fluid mixture;contacting the anti-solvent fluid with said solution or suspension of atleast one polymer to form a combined stream containing the supercriticalor a near-critical fluid mixture, the vehicle and the polymer;

spraying the combined stream through an orifice of said tube into avessel, wherein said vehicle is extracted from the solution orsuspension and particles of the polymer substantially free of thevehicle are formed prior to deposition of said polymer particles on saidsubstrate;

depositing the polymer particles onto a substrate pre-coated withparticles of at least one pharmaceutical agent disposed into said vesselwherein an electrical potential is maintained between the substrate andthe polymer particles, thereby forming said coating; and

sintering said coating under conditions that do not substantially modifythe morphology of said solid pharmaceutical particles.

A further aspect provides a method for depositing a coating comprising apolymer and a biological agent on a substrate, comprising the followingsteps; forming a first stream of a polymer solution comprising a firstsolvent and at least one polymer;

forming a second stream of a supercritical or near critical fluidmixture, contacting said first and second streams, whereby saidsupercritical or near critical fluid acts as a diluent of said firstsolvent under conditions sufficient to form particles of the polymer;

forming a third stream of a solution comprising a second solvent and atleast one biological agent;

forming a fourth stream of a supercritical or near critical fluidmixture,

contacting said third and fourth streams, whereby said supercritical ornear critical fluid acts as a diluent of said second solvent underconditions sufficient to form particles of the pharmaceutical agent;

depositing the polymer and/or biological agent particles onto saidsubstrate, wherein an electrical potential is maintained between thesubstrate and the biological agent and/or polymer particles, therebyforming said coating; and

sintering said coating under conditions that do not substantially modifythe structure of said biological agent particles.

Yet another aspect provides a method for depositing a coating comprisinga polymer and a pharmaceutical agent on a substrate, comprising thefollowing steps;

forming a first stream of a solution comprising a solvent and at leastone pharmaceutical agent;

discharging said stream in a vessel containing said substrate and asupercritical or near critical fluid mixture, whereby said supercriticalor near critical fluid acts as a diluent of said solvent underconditions sufficient to form particles of the pharmaceutical agent;

forming a second stream of a solution comprising a solvent and at leastone polymer;

discharging said second stream in said vessel, whereby saidsupercritical or near critical fluid acts as a diluent of said solventunder conditions sufficient to form particles of the polymer

depositing the pharmaceutical and/or polymer particles onto saidsubstrate, wherein an electrical potential is maintained between thesubstrate and the pharmaceutical and/or polymer particles, therebyforming said coating; and

sintering said coating under conditions that do not substantially modifythe morphology of said solid pharmaceutical particles.

A further aspect provides a method for depositing a coating comprising apolymer and a pharmaceutical agent on a substrate, comprising thefollowing steps;

providing a substrate pre-coated with at least one polymer; forming astream of a solution comprising a solvent and at least onepharmaceutical agent;

discharging said stream in a vessel containing said substrate and asupercritical or near critical fluid mixture, whereby said supercriticalor near critical fluid acts as a diluent of said solvent underconditions sufficient to form particles of the pharmaceutical agent;

depositing the pharmaceutical particles onto said substrate, wherein anelectrical potential is maintained between the substrate and thepharmaceutical particles, thereby forming said coating; and

sintering said coating under conditions that do not substantially modifythe morphology of said solid pharmaceutical particles.

Another aspect provides a method for depositing a coating comprising apolymer and a pharmaceutical agent on a substrate, comprising thefollowing steps;

providing a substrate pre-coated with solid particles of at least onepharmaceutical agent; forming a stream of a solution comprising asolvent and at least one polymer;

discharging said stream in a vessel containing said substrate and asupercritical or near critical fluid mixture, whereby said supercriticalor near critical fluid acts as a diluent of said solvent underconditions sufficient to form particles of the polymer;

depositing the polymer particles onto said substrate, wherein anelectrical potential is maintained between the substrate and the polymerparticles, thereby forming said coating; and

sintering said coating under conditions that do not substantially modifythe morphology of said solid pharmaceutical particles.

Yet another aspect provides a method for depositing a coating comprisinga polymer and pharmaceutical agent on a substrate, wherein the methodcomprises the following steps:

contacting an anti-solvent fluid mixture which is a supercritical or anear-critical fluid mixture and a solution or suspension of at least onepharmaceutical agent in a vehicle which is soluble or substantiallysoluble in the anti-solvent fluid mixture to form a combined streamcontaining the supercritical or a near-critical fluid mixture, thevehicle and the pharmaceutical agent;

spraying the combined stream into a vessel, wherein said vehicle isextracted from the solution or suspension and particles of thepharmaceutical agent substantially free of the vehicle are formed priorto deposition of said pharmaceutical particles on a substrate pre-coatedwith particles of at least one polymer;

depositing the pharmaceutical particles onto said substrate disposedinto said vessel wherein an electrical potential is maintained betweenthe substrate and the pharmaceutical particles, thereby forming saidcoating; and

sintering said coating under conditions that do not substantially modifythe morphology of said solid pharmaceutical particles.

A further aspect of the invention provides a method for depositing acoating comprising a polymer and pharmaceutical agent on a substrate,wherein the method comprises the following steps:

contacting an anti-solvent fluid mixture which is a supercritical or anear-critical fluid mixture and a solution or suspension of at least onepharmaceutical agent in a vehicle which is soluble or substantiallysoluble in the anti-solvent fluid mixture to form a combined streamcontaining the supercritical or a near-critical fluid mixture, thevehicle and the pharmaceutical agent;

spraying the combined stream into a vessel, wherein said vehicle isextracted from the solution or suspension and particles of thepharmaceutical agent substantially free of the vehicle are formed priorto deposition of said pharmaceutical particles on a substrate pre-coatedwith particles of at least one polymer; wherein said anti-solventmixture and said solution or suspension of at least one pharmaceuticalagent are supplied by first and second tubes, respectively, wherein saidfirst and second tubes are disposed at an angle;

depositing the pharmaceutical particles onto said substrate disposedinto said vessel wherein an electrical potential is maintained betweenthe substrate and the polymer particles, thereby forming said coating;and

sintering said coating under conditions that do not substantially modifythe morphology of said solid pharmaceutical particles

A further aspect of the invention provides a method for depositing acoating comprising a polymer and at least two pharmaceutical agents on asubstrate, wherein the method comprises the following steps:

contacting an anti-solvent fluid mixture which is a supercritical or anear-critical fluid mixture, a solution or suspension of a firstpharmaceutical agent in a first vehicle which is soluble orsubstantially soluble in the anti-solvent fluid mixture, and a solutionor suspension of a second pharmaceutical agent in a second vehicle whichis the same as the first vehicle or another vehicle soluble orsubstantially soluble in the anti-solvent fluid mixture to form acombined stream containing the supercritical or a near-critical fluidmixture, the vehicle or vehicles and the first and second pharmaceuticalagents;

spraying the combined stream into a vessel, wherein said vehicle isextracted from the solution or suspension and particles of the first andsecond pharmaceutical agents substantially free of the vehicle orvehicles are formed prior to deposition of said pharmaceutical particleson a substrate pre-coated with particles of at least one polymer;wherein said anti-solvent mixture, said solution or suspension of saidfirst pharmaceutical agent, and said solution or suspension of saidsecond pharmaceutical agent are supplied by first, second and thirdtubes, respectively, wherein said second and third tubes are eachdisposed at an angle from said first tube;

depositing the pharmaceutical particles onto said substrate disposedinto said vessel wherein an electrical potential is maintained betweenthe substrate and the polymer particles, thereby forming said coating;and

sintering said coating under conditions that do not substantially modifythe morphology of said solid pharmaceutical particles

Yet another aspect provides a coated implantable medical device,comprising:

a substrate; and

a pharmaceutical agent-polymer coating having substantially uniformthickness disposed on the substrate, wherein the coating comprises atleast one pharmaceutical agent all of the pharmaceutical agent or agentsin the coating are substantially uniformly dispersed within the—polymercoating.

INCORPORATION BY REFERENCE

All publications and patent applications mentioned in this specificationare herein incorporated by reference to the same extent as if eachindividual publication or patent application was specifically andindividually indicated to be incorporated by reference.

BRIEF DESCRIPTION OF THE DRAWINGS

The novel features of the invention are set forth with particularity inthe appended claims. A better understanding of the features andadvantages of the present invention will be obtained by reference to thefollowing detailed description that sets forth illustrative embodiments,in which the principles of the invention are utilized, and theaccompanying drawings of which:

FIG. 1. Rapid Expansion of Supercritical Solutions (RESS) processequipment. See C. Domingo et al, Journal of Supercritical Fluids 10,39-55 (1997)

FIG. 2. Solution Enhanced Dispersion of Supercritical solutions (SEDS)process equipment.

FIG. 3. SEDS nozzle design.

FIG. 4. FTIR spectra of each individual component and the spray coatingmixture. Individual peaks for each component are labeled.

FIG. 5. Stents coated (a), (b) and sintered under different conditions(c), (d) with rapamycin, PEVA and PBMA (approximately 1:1:1). All stentsurfaces are coated.

FIG. 6. IR spectra of Si wafer chips coated with Rapamycin, PEVA andPBMA before and after sintering. No differences are observable betweenthe two spectra. The baseline shift at larger wavenumber in the asdeposited spectrum is due to light scattering caused by the largeparticle size.

FIG. 7. Crystalline spray-coated rapamycin using a process of thepresent invention.

FIG. 8. XRD spectra of rapamycin sprayed in two morphologies compared toan authentic sample.

FIG. 9. Particle size control.

FIG. 10. Further apparatus of the invention.

FIG. 11. Cloud point isotherms for polyethylene-co-vinyl acetate (PEVA)and poly(butyl methacrylate) (PMBA) combined as discussed in examples 9,10, 11 and 12.

FIG. 12. Schematic Representation of the Coating and Sintering ProcessApparatus, as discussed in example 9.

FIG. 13. Detailed images of the coating and sintering process apparatus,as discussed in example 9.

FIG. 14. Drug-Polymer coated coronary stent (a) immediately afterdeposition, (b) after annealing in a dense carbon dioxide environment at40° C. The photographs correspond to the experiment discussed in example10.

FIG. 15. 40× Magnified Images of Rapamycin/PEVA/PBMA Coated Stents,Obtained From an Optical Microscope with Back and Side Lighting, Showingthe Outside, Edge and Inside Surfaces, (a) before and (b) aftersintering, as discussed in example 10.

FIG. 16. 40× Magnified Images of Rapamycin/PEVA/PBMA Coated Stents,Obtained From an Optical Microscope with Back and Side Lighting, Showingthe Outside and Inside Surfaces, (a) before and (b) after sintering, asdiscussed in example 10.

FIG. 17. 100× Magnified Image of a Rapamycin/PEVA/PBMA Coated Stent,Obtained From an Optical Microscope. Crystalline drug is clearly visibleembedded within a highly uniform polymer coating, as discussed inexample 10.

FIG. 18. Scanning Electron Microscope Images of Rapamycin/PEVA/PBMACoated Stents, at (a) ×30 magnification, (b) ×250 magnification, (c)×1000 magnification and (d) ×3000 magnification, as discussed in example11.

FIG. 19. Cross-sectional Scanning Electron Microscope Images ofRapamycin/PEVA/PBMA Coated Stents at (a) ×7000 magnification and (b)×20000 magnification. Four cross-sectional thicknesses measured: (1)10.355 μM; (2) 10.412 μM; (3) 10.043 μM and (4) 10.157 μM, providing acalculated average thickness of 10.242 μM ±2%, also discussed in example11.

FIG. 20. Differential Scanning calorimetry (DSC) of (a) PEVA Control,(b) PBMA Control, (c) Rapamycin Control and (d) Coated Rapamycin, PEVA,PBMA Mixture. The Rapamycin crystalline melt at 185-200° C. is indicatedin (c) and (d), as discussed in example 12.

FIG. 21. X-Ray Diffraction of (a) Microionized Rapamycin Powder(Control) and (b) Coated Sintered Rapamycin/PEVA/PBMA Stents, asdiscussed in example 13.

FIG. 22. Confocal Raman Analysis of Rapamycin/PEVA/PBMA Coated Stents(i.e. Depth Profiling from Coating Surface to Metal Stent), highlighting(a) Rapamycin Depth Profile Outside Circumference and (b) Polymer DepthProfile Outside Circumference, as discussed in example 14.

FIG. 23. (a) Rapamycin UV-Vis Spectrum and (b) Calibration Curve at 277nm. (c) PEVA/PBMA FT-IR Spectrum, (d) PEVA Calibration Curve at 1050 nmand (e) PBMA Calibration Curve at 1285 nm.

FIG. 24. Quantification of Coating Components, (mean concentrations (3stents each); 4 cell by 8 mm parylene coated). (a) RapamycinQuantification (74±11 μg) Using UV-Vis Method; (b) PEVA (1060±190 μg)and (c) PBMA (1110±198 μg) Quantification Using FT-IR Method, asdiscussed in example 15.

FIG. 25. Optical Microscopy Showing the Outside Surface of a 3 mmGuidant TriStar® Stent Coated with Paclitaxel-polymer composite, asdiscussed in example 16.

FIG. 26. Paclitaxel Quantification After Coating on a 3 mm GuidantTriStar® Stent with Paclitaxel/PEVA/PMBA composite, as discussed inexample 16. (a) Calibration Curve at 228 nm in ethanol Using UV-VisStandard Method and (b) Quantification (148±14 μg) Using UV-Vis Method.

FIG. 27. Quantification of Coating Components, (mean concentrations (3stents each); 6 cell by 8 mm parylene coated). (a) RapamycinQuantification (81±3 μg) Using UV-Vis Method; (b) PEVA (391±69 μg) and(c) PBMA (268±64 μg) Quantification Using FT-IR Method, as discussed inexample 17.

FIG. 28. Shows a graphical summary of conditions employed in sinteringexperiments according to embodiments of the invention.

FIGS. 29 and 30 illustrate elution profiles for stents coated accordingto embodiments of the invention.

FIG. 31 illustrates mechanical stability of stents coated according toembodiments of the invention.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is explained in greater detail below. Thisdescription is not intended to be a detailed catalog of all thedifferent ways in which the invention may be implemented, or all thefeatures that may be added to the instant invention. For example,features illustrated with respect to one embodiment may be incorporatedinto other embodiments, and features illustrated with respect to aparticular embodiment may be deleted from that embodiment. In addition,numerous variations and additions to the various embodiments suggestedherein will be apparent to those skilled in the art in light of theinstant disclosure, which do not depart from the instant invention.Hence, the following specification is intended to illustrate someparticular embodiments of the invention, and not to exhaustively specifyall permutations, combinations and variations thereof.

Applicants specifically intend that all United States patent referencescited herein be incorporated herein by reference in their entirety.

The present invention provides a cost-effective, efficient method fordepositing a combination of an inert polymer or polymers and apharmaceutical or biological agent or agents, onto parts or all surfacesof a substrate, to form a coating that is of a pre-determined, desiredthickness, conformal, substantially defect-free, and uniform and thecomposition of the coating can be regulated. In particular, the presentinvention addresses the problem of existing coating processes, which donot allow for structural and morphological preservation of the agentsdeposited during the coating process.

One aspect of the invention entails the deposition of the pharmaceuticalor biological agents as dry powders, using electrostatic capture toattract the powder particles to the substrate. Dry powder spraying iswell known in the art, and dry powder spraying coupled withelectrostatic capture has been described, for example in U.S. Pat. Nos.5,470,603 6,319,541 or 6,372,246. The deposition of the polymer can beperformed in any number of standard procedures, as the morphology of thepolymer, so long as it provides coatings possessing the desiredproperties (e.g. thickness, conformity, defect-free, uniformity etc), isof less importance. The function of the polymer is primarily one ofinert carrier matrix for the active components of the coating.

In one aspect, the coating process involves taking the substrates thathave been coated with pharmaceutical or biological agents and polymersand subjecting them to a sintering process that takes place under benignconditions, which do not significantly affect the structural andmorphological integrity of the pharmaceutical and biological agents. Thesintering process as used in the current invention refers to the processby which parts of the matrix or the entire polymer matrix becomescontinuous (e.g., formation of a continuous polymer film). As discussedbelow, the sintering process is controlled to produce a fully conformalcontinuous matrix (complete sintering) or to produce regions or domainsof continuous coating while producing voids (discontinuities) in thematrix. As well, the sintering process is controlled such that somephase separation is obtained between polymer different polymers (e.g.,polymers A and B) and/or to produce phase separation between discretepolymer particles. The sintering process also improves the adhesion ofthe polymer coating. The sintering process involves treatment of thecoated substrate with a compressed gas, compressed liquid, orsupercritical fluid at conditions (e.g. temperature and pressure) suchthat it is a poor solvent or in some instances a non-solvent for thepolymers, the pharmaceutical agents and the biological agents, butinduces the formation of a continuous coating of polymer. The sinteringprocess takes place under conditions (e.g. mild temperatures), and usingbenign fluids (e.g. a compressed gas, or supercritical fluid, the gas orfluid may comprise carbon dioxide, isobutylene or a mixture thereof forexample) which will not significantly affect the structural andmorphological integrity of the pharmaceutical and/or biological agents.It is noted that while under some situations better sintering resultsmay be obtained by using supercritical or near critical fluids, in manyembodiments according to the invention, treatment with compressed gaswill provide the desired sintered polymer coating. Those of skill in theart will have no difficulty selecting a supercritical fluid, a nearcritical fluid or compressed gas in practicing the present invention.Sintering conditions may be adjusted such that the sintering process isnot fully completed. That is, the sintering does not result in theformation of a fully continuous polymer matrix. When incompletesintering is practiced according to the invention, some domains in thepolymer matrix may be continuous, while other domains will define voids,cavities, pores, channels or interstices where the drug can beencapsulated or sequestered within the polymer matrix. Such a polymermatrix would be at a density less than the bulk density of the polymer;caused by micro or macroscopic voids in the polymer matrix.Alternatively, such a polymer matrix could retain phase separation ofthe polymer domains or in the case where multiple polymers are used,phase separation between the different polymer species. In mostembodiments, whether the sintering process is complete or incomplete,the sintering conditions are selected to produce good adhesion of thecoating to the substrate. For stents, adequate adhesion properties willgenerally reduce or prevent flaking or detachment of the coating fromthe stent during manipulation in use.

One aspect of the invention is the combination of two or more of the drypowder, RESS and SEDS spraying techniques.

Another aspect of the invention involves the dry powder spraying of apharmaceutical agent, in a preferred particle size and morphology, intothe same capture vessel as a polymer that is also dry powder sprayed,whereby the spraying of the agent and the polymer is sequential orsimultaneous.

Another specific aspect of the invention involves the dry powderspraying of an active biological agent, in a preferred particle size andpossessing a particular activity, into the same capture vessel as apolymer that is also dry powder sprayed, whereby the spraying of theagent and the polymer is sequential or simultaneous.

Yet another aspect of the invention involves the dry powder spraying ofa pharmaceutical agent, in a preferred particle size and morphology,into the same capture vessel as a polymer that is sequentially orsimultaneously sprayed by the RESS spray process.

Yet another aspect of the invention involves the dry powder spraying ofan active biological agent, in a preferred particle size and possessinga particular activity, into the same capture vessel as a polymer that issequentially or simultaneously sprayed by the RESS spray process.

Yet another aspect of the invention involves the dry powder spraying ofa pharmaceutical agent, in a preferred particle size and morphology,into the same capture vessel as a polymer that is sequentially orsimultaneously sprayed by the SEDS spray process.

Yet another aspect of the invention involves the dry powder spraying ofan active biological agent, in a preferred particle size and possessinga particular activity, into the same capture vessel as a polymer that issequentially or simultaneously sprayed by the SEDS spray process.

Any combination of the above six processes is contemplated by thisaspect of the invention.

In further aspects of the invention the substrates that have been coatedwith pharmaceutical or biological agents and polymers, as described inthe above embodiments are then subjected to a sintering process. Thesintering process takes place under benign conditions, which do notaffect the structural and morphological integrity of the pharmaceuticaland biological agents, and refers to a process by which the co-depositedpharmaceutical agent or biological agent-polymer matrix, becomescontinuous and adherent to the substrate. This is achieved by treatingthe coated substrate with a compressed gas, compressed liquid orsupercritical fluid at conditions such that it is a poor solvent of thepolymers, a weak solvent of the polymers or a non-solvent for thepolymers, the pharmaceutical agents and the biological agents, but anagent suitable for the treatment of polymer particles to form continuouspolymer coatings. The sintering process takes place under conditions(e.g. mild temperatures), and using benign fluids (e.g. supercriticalcarbon dioxide) which will not affect the structural and morphologicalintegrity of the pharmaceutical and biological agents. Other sinteringprocesses, which do not affect the structural and morphologicalintegrity of the pharmaceutical and biological agents may also becontemplated by the present invention.

In further aspects of the invention, it is desirable to create coatingssuch that release of an active substance occurs with a predeterminedelution profile when placed in the desired elution media. Coatingproperties can be modified in a variety of different ways in order toprovide desirable elution profiles.

The chemical composition of the polymers can be varied, to providegreater or lesser amounts of polymers that will allow or restrict theelution of active substance. For example, if the intended elution mediacontain water, a higher content of polymers that swell in water, willallow for a faster elution of active substance. Conversely, a highercontent of polymers that do not swell in aqueous media will result in aslower elution rate.

The coating properties can also be controlled by alternating polymerlayers. Layers of polymers of different properties are deposited on thesubstrate in a sequential manner. By modifying the nature of the polymerdeposited in each layer (e.g., depositing layers of different polymers)the elution profile of the coating is altered. The number of layers andthe sequence in their deposition provide additional avenues for thedesign of coatings having controlled elution profiles.

The coating properties can also be modified by control of the macroand/or micro-structure of the polymer coating (diffusion pathways). Thismay be achieved by varying the coating process(es) or by using differentsintering conditions.

The present invention provides several approaches for controlling theelution of a drug or several drugs. For example, in one embodiment,controlled elution is achieved by the segregation of different polymers(e.g. PEVA/PBMA). In another embodiment, control of elution is achievedby controlling the conditions during the sintering process such thatcontrolled incomplete sintering of the polymer matrix is obtained,whereby the coating would retain some of the particle-like structure ofthe polymer particles as deposited Incomplete sintering would providepores/voids in the coating and allow a additional pathways for elutionof the drug, including drug elution around the polymer(s) instead of orin addition to elution through the polymer(s). The size of the pores orvoids obtained through incomplete sintering of the polymer matrix may beobtained through several methods. For example, the rate ofdepressurization of a vessel in which the sintering process is carriedout provides one avenue for controlling pore size. The size of thecavities or pores in the coating can be controlled by employing aporogen as an excipient and subsequent removal of at least a portion ofthe porogen, for example by treatment with a solvent of the porogen.Preferably, the porogen solvent comprises a densified gas (e.g.;carbon). In some embodiments the porogen is an SOA or other suchhydrophobically derivatized carbohydrate. Removal of at least a portionof the porogen is preferably carried out during the sintering process.

In some aspects of the invention, the active substance elution profileis controllable by altering the polymer particle size. The method bywhich the polymer particles are deposited onto the substrate is thusvaried to provide the desired elution rate. For example, for polymersreleased simultaneously through the same nozzle, RESS release from asupercritical solution would typically result in small polymerparticles; RESS-like release from a mixture in a compressed gas usuallygenerates larger polymer particles. Using the SEDS process can result invariable polymer particle size, depending on the particular SEDSconditions employed.

In further aspects of the invention, the active substance elutionprofile is controllable by altering the polymer particle shape. One wayto achieve variation in polymer particle shape is to alter the initialconcentration of the polymers. At lower initial concentrations, polymersare deposited as small particles. At increased concentrations, largerparticles are formed. At higher concentrations, the formed particlesbecome elongated, until at high concentrations the elongated featuresbecome fiber-like and eventually become continuous fibers.

In yet other aspects of the invention, the active substance elutionprofile is controllable by creating discrete domains of chemicallydifferent polymers. As described above, chemically different polymerswill allow or restrict the elution of active substance in differentelution media. By changing the position of such polymers in discretemacroscopic domains within the coating, the elution profiles will beadjustable. For example during a process whereby two different polymersare released sequentially through the same nozzle, particles of eitherpolymer could be deposited to position them, for example, closer to theoutside, the inside or the middle of the coating on the substrate. Inanother embodiment, the two polymers may be released simultaneouslythrough two different nozzles at differing and/or alternating depositionrates, resulting in a similar effect. In a further embodiment, thedeposition of eluting and non-eluting polymers is alternated to resultin a fluctuating type of release. In yet other embodiments, the polymersare deposited to provide for a pulsatile release of active substance.Separation of the polymer(s) providing different domains for drugdiffusion is achieved, for example, by subsequent spray of the polymersthrough same nozzle or by using multiple nozzles. Also, as describedabove, controlling the elution of the active substance may be achievedby layering of different polymers across the depth of the coating. Acombination of domain separation and cross-depth layering is alsocontemplated for the design of coatings having controlled elutionproperties.

The deposition of active substance during any of these processes may beconstant to provide even distribution throughout the coating, or thespraying of the active substance may be varied to result in differingamounts of active substance in the differing polymeric domains withinthe coating.

In further aspects of the invention, the active substance elutionprofile is controllable by varying the coating sintering conditions. Forexample, incomplete sintering will create open spaces, or pores in theinterstitial spaces between the polymer particles, which will enablefaster eluting of active substance from the coating. Another way toutilize the sintering conditions for elution control would be todeliberately create irregular coatings by foaming during the sinteringprocess. Rapid pressure release of a CO₂— or isobutylene-impregnatedpolymer film induces formation of foamed polymers which would create acoating with increased porosity and be very ‘open’ to diffusion/elution.Thus the elution profile would be controllable by manipulating thefoaming conditions, which in turn controls the pore density and size.

DEFINITIONS

As used in the present specification, the following words and phrasesare generally intended to have the meanings as set forth below, exceptto the extent that the context in which they are used indicatesotherwise.

“Substrate” as used herein, refers to any surface upon which it isdesirable to deposit a coating comprising a polymer and a pharmaceuticalor biological agent, wherein the coating process does not substantiallymodify the morphology of the pharmaceutical agent or the activity of thebiological agent. Biomedical implants are of particular interest for thepresent invention; however the present invention is not intended to berestricted to this class of substrates. Those of skill in the art willappreciate alternate substrates that could benefit from the coatingprocess described herein, such as pharmaceutical tablet cores, as partof an assay apparatus or as components in a diagnostic kit (e.g. a teststrip).

“Biomedical implant” as used herein refers to any implant for insertioninto the body of a human or animal subject, including but not limited tostents (e.g., vascular stents), electrodes, catheters, leads,implantable pacemaker, cardioverter or defibrillator housings, joints,screws, rods, ophthalmic implants, femoral pins, bone plates, grafts,anastomotic devices, perivascular wraps, sutures, staples, shunts forhydrocephalus, dialysis grafts, colostomy bag attachment devices, eardrainage tubes, leads for pace makers and implantable cardioverters anddefibrillators, vertebral disks, bone pins, suture anchors, hemostaticbarriers, clamps, screws, plates, clips, vascular implants, tissueadhesives and sealants, tissue scaffolds, various types of dressings(e.g., wound dressings), bone substitutes, intraluminal devices,vascular supports, etc.

The implants may be formed from any suitable material, including but notlimited to organic polymers (including stable or inert polymers andbiodegradable polymers), metals, inorganic materials such as silicon,and composites thereof, including layered structures with a core of onematerial and one or more coatings of a different material. Substratesmade of a conducting material facilitate electrostatic capture. However,the invention contemplates the use of electrostatic capture inconjunction with substrate having low conductivity or whichnon-conductive. To enhance electrostatic capture when a non-conductivesubstrate is employed, the substrate is processed while maintaining astrong electrical field in the vicinity of the substrate.

Subjects into which biomedical implants of the invention may be appliedor inserted include both human subjects (including male and femalesubjects and infant, juvenile, adolescent, adult and geriatric subjects)as well as animal subjects (including but not limited to dog, cat,horse, monkey, etc.) for veterinary purposes.

In a preferred embodiment the biomedical implant is an expandableintraluminal vascular graft or stent (e.g., comprising a wire mesh tube)that can be expanded within a blood vessel by an angioplasty balloonassociated with a catheter to dilate and expand the lumen of a bloodvessel, such as described in U.S. Pat. No. 4,733,665 to Palmaz Shaz.

“Pharmaceutical agent” as used herein refers to any of a variety ofdrugs or pharmaceutical compounds that can be used as active agents toprevent or treat a disease (meaning any treatment of a disease in amammal, including preventing the disease, i.e. causing the clinicalsymptoms of the disease not to develop; inhibiting the disease, i.e.arresting the development of clinical symptoms; and/or relieving thedisease, i.e. causing the regression of clinical symptoms). It ispossible that the pharmaceutical agents of the invention may alsocomprise two or more drugs or pharmaceutical compounds. Pharmaceuticalagents, include but are not limited to antirestenotic agents,antidiabetics, analgesics, antiinflammatory agents, antirheumatics,antihypotensive agents, antihypertensive agents, psychoactive drugs,tranquillizers, antiemetics, muscle relaxants, glucocorticoids, agentsfor treating ulcerative colitis or Crohn's disease, antiallergics,antibiotics, antiepileptics, anticoagulants, antimycotics, antitussives,arteriosclerosis remedies, diuretics, proteins, peptides, enzymes,enzyme inhibitors, gout remedies, hormones and inhibitors thereof,cardiac glycosides, immunotherapeutic agents and cytokines, laxatives,lipid-lowering agents, migraine remedies, mineral products, otologicals,anti parkinson agents, thyroid therapeutic agents, spasmolytics,platelet aggregation inhibitors, vitamins, cytostatics and metastasisinhibitors, phytopharmaceuticals, chemotherapeutic agents and aminoacids. Examples of suitable active ingredients are acarbose, antigens,beta-receptor blockers, non-steroidal antiinflammatory drugs {NSAIDs],cardiac glycosides, acetylsalicylic acid, virustatics, aclarubicin,acyclovir, cisplatin, actinomycin, alpha- and beta-sympatomimetics,(dmeprazole, allopurinol, alprostadil, prostaglandins, amantadine,ambroxol, amlodipine, methotrexate, S-aminosalicylic acid,amitriptyline, amoxicillin, anastrozole, atenolol, azathioprine,balsalazide, beclomethasone, betahistine, bezafibrate, bicalutamide,diazepam and diazepam derivatives, budesonide, bufexamac, buprenorphine,methadone, calcium salts, potassium salts, magnesium salts, candesartan,carbamazepine, captopril, cefalosporins, cetirizine, chenodeoxycholicacid, ursodeoxycholic acid, theophylline and theophylline derivatives,trypsins, cimetidine, clarithromycin, clavulanic acid, clindamycin,clobutinol, clonidine, cotrimoxazole, codeine, caffeine, vitamin D andderivatives of vitamin D, colestyramine, cromoglicic acid, coumarin andcoumarin derivatives, cysteine, cytarabine, cyclophosphamide,ciclosporin, cyproterone, cytabarine, dapiprazole, desogestrel,desonide, dihydralazine, diltiazem, ergot alkaloids, dimenhydrinate,dimethyl sulphoxide, dimeticone, domperidone and domperidan derivatives,dopamine, doxazosin, doxorubizin, doxylamine, dapiprazole,benzodiazepines, diclofenac, glycoside antibiotics, desipramine,econazole, ACE inhibitors, enalapril, ephedrine, epinephrine, epoetinand epoetin derivatives, morphinans, calcium antagonists, irinotecan,modafinil, orlistat, peptide antibiotics, phenyloin, riluzoles,risedronate, sildenafil, topiramate, macrolide antibiotics, oestrogenand oestrogen derivatives, progestogen and progestogen derivatives,testosterone and testosterone derivatives, androgen and androgenderivatives, ethenzamide, etofenamate, etofibrate, fenofibrate,etofylline, etoposide, famciclovir, famotidine, felodipine, fenofibrate,fentanyl, fenticonazole, gyrase inhibitors, fluconazole, fludarabine,fluarizine, fluorouracil, fluoxetine, flurbiprofen, ibuprofen,flutamide, fluvastatin, follitropin, formoterol, fosfomicin, furosemide,fusidic acid, gallopamil, ganciclovir, gemfibrozil, gentamicin, ginkgo,Saint John's wort, glibenclamide, urea derivatives as oralantidiabetics, glucagon, glucosamine and glucosamine derivatives,glutathione, glycerol and glycerol derivatives, hypothalamus hormones,goserelin, gyrase inhibitors, guanethidine, halofantrine, haloperidol,heparin and heparin derivatives, hyaluronic acid, hydralazine,hydrochlorothiazide and hydrochlorothiazide derivatives, salicylates,hydroxyzine, idarubicin, ifosfamide, imipramine, indometacin,indoramine, insulin, interferons, iodine and iodine derivatives,isoconazole, isoprenaline, glucitol and glucitol derivatives,itraconazole, ketoconazole, ketoprofen, ketotifen, lacidipine,lansoprazole, levodopa, levomethadone, thyroid hormones, lipoic acid andlipoic acid derivatives, lisinopril, lisuride, lofepramine, lomustine,loperamide, loratadine, maprotiline, mebendazole, mebeverine, meclozine,mefenamic acid, mefloquine, meloxicam, mepindolol, meprobamate,meropenem, mesalazine, mesuximide, metamizole, metformin, methotrexate,methylphenidate, methylprednisolone, metixene, metoclopramide,metoprolol, metronidazole, mianserin, miconazole, minocycline,minoxidil, misoprostol, mitomycin, mizolastine, moexipril, morphine andmorphine derivatives, evening primrose, nalbuphine, naloxone, tilidine,naproxen, narcotine, natamycin, neostigmine, nicergoline, nicethamide,nifedipine, niflumic acid, nimodipine, nimorazole, nimustine,nisoldipine, adrenaline and adrenaline derivatives, norfloxacin,novamine sulfone, noscapine, nystatin, ofloxacin, olanzapine,olsalazine, omeprazole, omoconazole, ondansetron, oxaceprol, oxacillin,oxiconazole, oxymetazoline, pantoprazole, paracetamol, paroxetine,penciclovir, oral penicillins, pentazocine, pentifylline,pentoxifylline, perphenazine, pethidine, plant extracts, phenazone,pheniramine, barbituric acid derivatives, phenylbutazone, phenyloin,pimozide, pindolol, piperazine, piracetam, pirenzepine, piribedil,piroxicam, pramipexole, pravastatin, prazosin, procaine, promazine,propiverine, propranolol, propyphenazone, prostaglandins, protionamide,proxyphylline, quetiapine, quinapril, quinaprilat, ramipril, ranitidine,reproterol, reserpine, ribavirin, rifampicin, risperidone, ritonavir,ropinirole, roxatidine, roxithromycin, ruscogenin, rutoside and rutosidederivatives, sabadilla, salbutamol, salmeterol, scopolamine, selegiline,sertaconazole, sertindole, sertralion, silicates, sildenafil,simvastatin, sitosterol, sotalol, spaglumic acid, sparfloxacin,spectinomycin, spiramycin, spirapril, spironolactone, stavudine,streptomycin, sucralfate, sufentanil, sulbactam, sulphonamides,sulfasalazine, sulpiride, sultamicillin, sultiam, sumatriptan,suxamethonium chloride, tacrine, tacrolimus, taliolol, tamoxifen,taurolidine, tazarotene, temazepam, teniposide, tenoxicam, terazosin,terbinafine, terbutaline, terfenadine, terlipressin, tertatolol,tetracycline, teryzoline, theobromine, theophylline, butizine,thiamazole, phenothiazines, thiotepa, tiagabine, tiapride, propionicacid derivatives, ticlopidine, timolol, timidazole, tioconazole,tioguanine, tioxolone, tiropramide, tizanidine, tolazoline, tolbutamide,tolcapone, tolnaftate, tolperisone, topotecan, torasemide,antioestrogens, tramadol, tramazoline, trandolapril, tranylcypromine,trapidil, trazodone, triamcinolone and triamcinolone derivatives,triamterene, trifluperidol, trifluridine, trimethoprim, trimipramine,tripelennamine, triprolidine, trifosfamide, tromantadine, trometamol,tropalpin, troxerutine, tulobuterol, tyramine, tyrothricin, urapidil,ursodeoxycholic acid, chenodeoxycholic acid, valaciclovir, valproicacid, vancomycin, vecuronium chloride, Viagra, venlafaxine, verapamil,vidarabine, vigabatrin, viloazine, vinblastine, vincamine, vincristine,vindesine, vinorelbine, vinpocetine, viquidil, warfarin, xantinolnicotinate, xipamide, zafirlukast, zalcitabine, zidovudine,zolmitriptan, zolpidem, zoplicone, zotipine and the like. See, e.g.,U.S. Pat. No. 6,897,205; see also U.S. Pat. No. 6,838,528; U.S. Pat. No.6,497,729.

Examples of therapeutic agents employed in conjunction with theinvention include, rapamycin, 40-O-(2-Hydroxyethyl)rapamycin(everolimus), 40-O-Benzyl-rapamycin,40-O-(4′-Hydroxymethyl)benzyl-rapamycin,40-O-[4′-(1,2-Dihydroxyethyl)]benzyl-rapamycin, 40-O-Allyl-rapamycin,40-O-[3′-(2,2-Dimethyl-1,3-dioxolan-4(S)-yl)-prop-2′-en-1′-yl]-rapamycin,(2′:E,4′S)-40-O-(4′,5′-Dihydroxypent-2′-en-1′-yl)-rapamycin40-O-(2-Hydroxy)ethoxycarbonylmethyl-rapamycin,40-O-(3-Hydroxy)propyl-rapamycin 4O-O-(6-Hydroxy)hexyl-rapamycin40-O-[2-(2-Hydroxy)ethoxy]ethyl-rapamycin4O-O-[(3S)-2,2-Dimethyldioxolan-3-yl]methyl-rapamycin,40-O-[(2S)-2,3-Dihydroxyprop-1-yl]-rapamycin,4O-O-(2-Acetoxy)ethyl-rapamycin 4O-O-(2-Nicotinoyloxy)ethyl-rapamycin,4O-O-[2-(N-Morpholino)acetoxy]ethyl-rapamycin4O-O-(2-N-Imidazolylacetoxy)ethyl-rapamycin,40-O-[2-(N-Methyl-N′-piperazinyl)acetoxy]ethyl-rapamycin,39-O-Desmethyl-39,40-O,O-ethylene-rapamycin,(26R)-26-Dihydro-40-O-(2-hydroxy)ethyl-rapamycin, 28-O-Methyl-rapamycin,4O-O-(2-Aminoethyl)-rapamycin, 4O-O-(2-Acetaminoethyl)-rapamycin4O-O-(2-Nicotinamidoethyl)-rapamycin,4O-O-(2-(N-Methyl-imidazo-2′-ylcarbethoxamido)ethyl)-rapamycin,4O-O-[2-Ethoxycarbonylaminoethyl)-rapamycin,40-O-(2-Tolylsulfonamidoethyl)-rapamycin,40-O-[2-(4′,5′-Dicarboethoxy-1′,2′,3′-triazol-1′-yl)-ethyl]-rapamycin,42-Epi-(tetrazolyl)rapamycin (tacrolimus), and42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin(temsirolimus).

The active ingredients may, if desired, also be used in the form oftheir pharmaceutically acceptable salts or derivatives (meaning saltswhich retain the biological effectiveness and properties of thecompounds of this invention and which are not biologically or otherwiseundesirable), and in the case of chiral active ingredients it ispossible to employ both optically active isomers and racemates ormixtures of diastereoisomers.

“Stability” as used herein in refers to the stability of the drug in apolymer coating deposited on a substrate in its final product form(e.g., stability of the drug in a coated stent). The term stability willdefine 5% or less degradation of the drug in the final product form.

“Active biological agent” as used herein refers to a substance,originally produced by living organisms, that can be used to prevent ortreat a disease (meaning any treatment of a disease in a mammal,including preventing the disease, i.e. causing the clinical symptoms ofthe disease not to develop; inhibiting the disease, i.e. arresting thedevelopment of clinical symptoms; and/or relieving the disease, i.e.causing the regression of clinical symptoms). It is possible that theactive biological agents of the invention may also comprise two or moreactive biological agents or an active biological agent combined with apharmaceutical agent, a stabilizing agent or chemical or biologicalentity. Although the active biological agent may have been originallyproduced by living organisms, those of the present invention may alsohave been synthetically prepared, or by methods combining biologicalisolation and synthetic modification. By way of a non-limiting example,a nucleic acid could be isolated form from a biological source, orprepared by traditional techniques, known to those skilled in the art ofnucleic acid synthesis. Furthermore, the nucleic acid may be furthermodified to contain non-naturally occurring moieties. Non-limitingexamples of active biological agents include peptides, proteins,enzymes, glycoproteins, nucleic acids (including deoxyribonucleotide orribonucleotide polymers in either single or double stranded form, andunless otherwise limited, encompasses known analogues of naturalnucleotides that hybridize to nucleic acids in a manner similar tonaturally occurring nucleotides), antisense nucleic acids, fatty acids,antimicrobials, vitamins, hormones, steroids, lipids, polysaccharides,carbohydrates and the like. They further include, but are not limitedto, antirestenotic agents, antidiabetics, analgesics, antiinflammatoryagents, antirheumatics, antihypotensive agents, antihypertensive agents,psychoactive drugs, tranquillizers, antiemetics, muscle relaxants,glucocorticoids, agents for treating ulcerative colitis or Crohn'sdisease, antiallergics, antibiotics, antiepileptics, anticoagulants,antimycotics, antitussives, arteriosclerosis remedies, diuretics,proteins, peptides, enzymes, enzyme inhibitors, gout remedies, hormonesand inhibitors thereof, cardiac glycosides, immunotherapeutic agents andcytokines, laxatives, lipid-lowering agents, migraine remedies, mineralproducts, otologicals, anti parkinson agents, thyroid therapeuticagents, spasmolytics, platelet aggregation inhibitors, vitamins,cytostatics and metastasis inhibitors, phytopharmaceuticals andchemotherapeutic agents. Preferably, the active biological agent is apeptide, protein or enzyme, including derivatives and analogs of naturalpeptides, proteins and enzymes.

“Activity” as used herein refers to the ability of a pharmaceutical oractive biological agent to prevent or treat a disease (meaning anytreatment of a disease in a mammal, including preventing the disease,i.e. causing the clinical symptoms of the disease not to develop;inhibiting the disease, i.e. arresting the development of clinicalsymptoms; and/or relieving the disease, i.e. causing the regression ofclinical symptoms). Thus the activity of a pharmaceutical or activebiological agent should be of therapeutic or prophylactic value.

“Secondary, tertiary and quaternary structure” as used herein aredefined as follows. The active biological agents of the presentinvention will typically possess some degree of secondary, tertiaryand/or quaternary structure, upon which the activity of the agentdepends. As an illustrative, non-limiting example, proteins possesssecondary, tertiary and quaternary structure. Secondary structure refersto the spatial arrangement of amino acid residues that are near oneanother in the linear sequence. The α-helix and the β-strand areelements of secondary structure. Tertiary structure refers to thespatial arrangement of amino acid residues that are far apart in thelinear sequence and to the pattern of disulfide bonds. Proteinscontaining more than one polypeptide chain exhibit an additional levelof structural organization. Each polypeptide chain in such a protein iscalled a subunit. Quaternary structure refers to the spatial arrangementof subunits and the nature of their contacts. For example hemoglobinconsists of two α and two β chains. It is well known that proteinfunction arises from its conformation or three dimensional arrangementof atoms (a stretched out polypeptide chain is devoid of activity). Thusone aspect of the present invention is to manipulate active biologicalagents, while being careful to maintain their conformation, so as not tolose their therapeutic activity.

“Polymer” as used herein, refers to a series of repeating monomericunits that have been cross-linked or polymerized. Any suitable polymercan be used to carry out the present invention. It is possible that thepolymers of the invention may also comprise two, three, four or moredifferent polymers. In some embodiments, of the invention only onepolymer is used. In some preferred embodiments a combination of twopolymers are used. Combinations of polymers can be in varying ratios, toprovide coatings with differing properties. Those of skill in the art ofpolymer chemistry will be familiar with the different properties ofpolymeric compounds. Examples of polymers that may be used in thepresent invention include, but are not limited to polycarboxylic acids,cellulosic polymers, proteins, polypeptides, polyvinylpyrrolidone,maleic anhydride polymers, polyamides, polyvinyl alcohols, polyethyleneoxides, glycosaminoglycans, polysaccharides, polyesters, polyurethanes,polystyrenes, copolymers, silicones, polyorthoesters, polyanhydrides,copolymers of vinyl monomers, polycarbonates, polyethylenes,polypropylenes, polylactic acids, polyglycolic acids, polycaprolactones,polyhydroxybutyrate valerates, polyacrylamides, polyethers, polyurethanedispersions, polyacrylates, acrylic latex dispersions, polyacrylic acid,mixtures and copolymers thereof. The polymers of the present inventionmay be natural or synthetic in origin, including gelatin, chitosan,dextrin, cyclodextrin, Poly(urethanes), Poly(siloxanes) or silicones,Poly(acrylates) such as poly(methyl methacrylate), poly(butylmethacrylate), and Poly(2-hydroxy ethyl methacrylate), Poly(vinylalcohol) Poly(olefins) such as poly(ethylene), poly(isoprene),halogenated polymers such as Poly(tetrafluoroethylene)—and derivativesand copolymers such as those commonly sold as Teflon® products,Poly(vinylidine fluoride), Poly(vinyl acetate), Poly(vinyl pyrrolidone),Poly(acrylic acid), Polyacrylamide, Poly(ethylene-co-vinyl acetate),Poly(ethylene glycol), Poly(propylene glycol), Poly(methacrylic acid);etc. Suitable polymers also include absorbable and/or resorbablepolymers including the following, combinations, copolymers andderivatives of the following: Polylactides (PLA), Polyglycolides (PGA),Poly(lactide-co-glycolides) (PLGA), Polyanhydrides, Polyorthoesters,Poly(N-(2-hydroxypropyl)methacrylamide), Poly(1-aspartamide), etc.

“Therapeutically desirable morphology” as used herein refers to thegross form and structure of the pharmaceutical agent, once deposited onthe substrate, so as to provide for optimal conditions of ex vivostorage, in vivo preservation and/or in vivo release. Such optimalconditions may include, but are not limited to increased shelf life,increased in vivo stability, good biocompatibility, good bioavailabilityor modified release rates. Typically, for the present invention, thedesired morphology of a pharmaceutical agent would be crystalline orsemi-crystalline or amorphous, although this may vary widely dependingon many factors including, but not limited to, the nature of thepharmaceutical agent, the disease to be treated/prevented, the intendedstorage conditions for the substrate prior to use or the location withinthe body of any biomedical implant. Preferably at least 10%, 20%, 30%,40%, 50%, 60%, 70%, 80%, 90% or 100% of the pharmaceutical agent is incrystalline or semi-crystalline form.

“Stabilizing agent” as used herein refers to any substance thatmaintains or enhances the stability of the biological agent. Ideallythese stabilizing agents are classified as Generally Regarded As Safe(GRAS) materials by the US Food and Drug Administration (FDA). Examplesof stabilizing agents include, but are not limited to carrier proteins,such as albumin, gelatin, metals or inorganic salts. Pharmaceuticallyacceptable excipient that may be present can further be found in therelevant literature, for example in the Handbook of PharmaceuticalAdditives: An International Guide to More Than 6000 Products by TradeName, Chemical, Function, and Manufacturer; Michael and Irene Ash(Eds.); Gower Publishing Ltd.; Aldershot, Hampshire, England, 1995.

“Compressed fluid” as used herein refers to a fluid of appreciabledensity (e.g., >0.2 g/cc) that is a gas at standard temperature andpressure. “Supercritical fluid”, “near-critical fluid”,“near-supercritical fluid”, “critical fluid”, “densified fluid” or“densified gas” as used herein refers to a compressed fluid underconditions wherein the temperature is at least 80% of the criticaltemperature of the fluid and the pressure is at least 50% of thecritical pressure of the fluid.

Examples of substances that demonstrate supercritical or near criticalbehavior suitable for the present invention include, but are not limitedto carbon dioxide, isobutylene, ammonia, water, methanol, ethanol,ethane, propane, butane, pentane, dimethyl ether, xenon, sulfurhexafluoride, halogenated and partially halogenated materials such aschlorofluorocarbons, hydrochlorofluorocarbons, hydrofluorocarbons,perfluorocarbons (such as perfluoromethane and perfluoropropane,chloroform, trichloro-fluoromethane, dichloro-difluoromethane,dichloro-tetrafluoroethane) and mixtures thereof.

“Sintering” as used herein refers to the process by which parts of thematrix or the entire polymer matrix becomes continuous (e.g., formationof a continuous polymer film). As discussed below, the sintering processis controlled to produce a fully conformal continuous matrix (completesintering) or to produce regions or domains of continuous coating whileproducing voids (discontinuities) in the matrix. As well, the sinteringprocess is controlled such that some phase separation is obtainedbetween polymer different polymers (e.g., polymers A and B) and/or toproduce phase separation between discrete polymer particles. Through thesintering process, the adhesions properties of the coating are improvedto reduce flaking of detachment of the coating from the substrate duringmanipulation in use. As described below, in some embodiments, thesintering process is controlled to provide incomplete sintering of thepolymer matrix. In embodiments involving incomplete sintering, a polymermatrix is formed with continuous domains, and voids, gaps, cavities,pores, channels or, interstices that provide space for sequestering atherapeutic agent which is released under controlled conditions.Depending on the nature of the polymer, the size of polymer particlesand/or other polymer properties, a compressed gas, a densified gas, anear critical fluid or a super-critical fluid may be employed. In oneexample, carbon dioxide is used to treat a substrate that has beencoated with a polymer and a drug, using dry powder and RESSelectrostatic coating processes. In another example, isobutylene isemployed in the sintering process. In other examples a mixture of carbondioxide and isobutylene is employed.

When an amorphous material is heated to a temperature above its glasstransition temperature, or when a crystalline material is heated to atemperature above a phase transition temperature, the moleculescomprising the material are more mobile, which in turn means that theyare more active and thus more prone to reactions such as oxidation.However, when an amorphous material is maintained at a temperature belowits glass transition temperature, its molecules are substantiallyimmobilized and thus less prone to reactions. Likewise, when acrystalline material is maintained at a temperature below its phasetransition temperature, its molecules are substantially immobilized andthus less prone to reactions. Accordingly, processing drug components atmild conditions, such as the deposition and sintering conditionsdescribed herein, minimizes cross-reactions and degradation of the drugcomponent. One type of reaction that is minimized by the processes ofthe invention relates to the ability to avoid conventional solventswhich in turn minimizes autoxidation of drug, whether in amorphous,semi-crystalline, or crystalline form, by reducing exposure thereof tofree radicals, residual solvents and autoxidation initiators.

“Rapid Expansion of Supercritical Solutions” or “RESS” as used hereininvolves the dissolution of a polymer into a compressed fluid, typicallya supercritical fluid, followed by rapid expansion into a chamber atlower pressure, typically near atmospheric conditions. The rapidexpansion of the supercritical fluid solution through a small opening,with its accompanying decrease in density, reduces the dissolutioncapacity of the fluid and results in the nucleation and growth ofpolymer particles. The atmosphere of the chamber is maintained in anelectrically neutral state by maintaining an isolating “cloud” of gas inthe chamber. Carbon dioxide or other appropriate gas is employed toprevent electrical charge is transferred from the substrate to thesurrounding environment.

“Bulk properties” properties of a coating including a pharmaceutical ora biological agent that can be enhanced through the methods of theinvention include for example: adhesion, smoothness, conformality,thickness, and compositional mixing.

“Solution Enhanced Dispersion of Supercritical Solutions” or “SEDS” asused herein involves a spray process for the generation of polymerparticles, which are formed when a compressed fluid (e.g. supercriticalfluid, preferably supercritical CO₂) is used as a diluent to a vehiclein which a polymer dissolved, (one that can dissolve both the polymerand the compressed gas). The mixing of the compressed fluid diluent withthe polymer-containing solution may be achieved by encounter of a firststream containing the polymer solution and a second stream containingthe diluent compressed fluid, for example, within one co-axial spraynozzle or by the use of multiple spray nozzles or by the use of multiplefluid streams co-entering into a mixing zone. The solvent in the polymersolution may be one compound or a mixture of two or more ingredients andmay be or comprise an alcohol (including diols, triols, etc.), ether,amine, ketone, carbonate, or alkanes, or hydrocarbon (aliphatic oraromatic) or may be a mixture of compounds, such as mixtures of alkanes,or mixtures of one or more alkanes in combination with additionalcompounds such as one or more alcohols. (e.g., from 0 or 0.1 to 5% of aC₁ to C₁₅ alcohol, including diols, triols, etc.). See for example U.S.Pat. No. 6,669,785. The solvent may optionally contain a surfactant, asalso described in (for example) U.S. Pat. No. 6,669,785.

In one embodiment of the SEDS process, a first stream of fluidcomprising a polymer dissolved in a common solvent is co-sprayed with asecond stream of compressed fluid. Polymer particles are produced as thesecond stream acts as a diluent that weakens the solvent in the polymersolution of the first stream. The now combined streams of fluid, alongwith the polymer particles, flow into a collection vessel. In anotherembodiment of the SEDS process, a first stream of fluid comprising adrug dissolved in a common solvent is co-sprayed with a second stream ofcompressed fluid. Drug particles are produced as the second stream actsas a diluent that weakens the solvent in the drug solution of the firststream. The now combined streams of fluid, along with the drugparticles, flow out into a collection vessel. Control of particle size,particle size distribution, and morphology is achieved by tailoring thefollowing process variables: temperature, pressure, solvent compositionof the first stream, flow-rate of the first stream, flow-rate of thesecond stream, composition of the second stream (where soluble additivesmay be added to the compressed gas), and conditions of the capturevessel. Typically the capture vessel contains a fluid phase that is atleast five to ten times (5-10×) atmospheric pressure.

“Electrostatically charged” or “electrical potential” or “electrostaticcapture” as used herein refers to the collection of the spray-producedparticles upon a substrate that has a different electrostatic potentialthan the sprayed particles. Thus, the substrate is at an attractiveelectronic potential with respect to the particles exiting, whichresults in the capture of the particles upon the substrate. i.e. thesubstrate and particles are oppositely charged, and the particlestransport through the fluid medium of the capture vessel onto thesurface of the substrate is enhanced via electrostatic attraction. Thismay be achieved by charging the particles and grounding the substrate orconversely charging the substrate and grounding the particles, or bysome other process, which would be easily envisaged by one of skill inthe art of electrostatic capture.

“Open vessel” as used herein refers to a vessel open to the outsideatmosphere, and thus at substantially the same temperature and pressureas the outside atmosphere.

“Closed vessel” as used herein refers to a vessel sealed from theoutside atmosphere, and thus may be at significantly differenttemperatures and pressures to the outside atmosphere.

EXAMPLES

The following examples are given to enable those skilled in the art tomore clearly understand and to practice the present invention. Theyshould not be considered as limiting the scope of the invention, butmerely as being illustrative and representative thereof.

Example 1 Process Equipment

The RESS process equipment used in the present studies is depicted inFIG. 1. This is a common design for a RESS apparatus see C. Domingo etal, Journal of Supercritical Fluids 10, 39-55 (1997). The SEDS equipmentused in the present studies is depicted in FIGS. 2 and 10. FIG. 2 showsa common SEDS apparatus and FIG. 10 shows a SEDS apparatus using atwo-nozzle design with electrostatic capture of the sprayed particles.The nozzle orifice size can be used to control the particle size. FIG. 3depicts the nozzle design for the SEDS equipment shown in FIGS. 2 and10. FIG. 4 shows the FTIR spectra of a representative small moleculemedically therapeutic agent, two polymers and the mixture of thecomponents. IR stretches specific to each molecule are identified andlabeled. FIG. 5 shows implantable medical devices coated withpharmaceutical agent and polymer under various sintering conditions.FIG. 6 shows the infrared spectra of the 3-component coating before andafter sintering. The spectra demonstrate that the sintering process doesnot adversely impact the coating since no new stretches appear in theafter sintering spectrum. FIG. 7 shows a wide (left panel) and narrow(right panel) field view of sprayed rapamycin. Both crystalline andamorphous rapamycin are visible in the images. FIG. 8 shows XRD datataken for an authentic rapamycin sample, RESS sprayed rapamycin and SEDSsprayed rapamycin. The RESS sprayed rapamycin lacks any crystallinityindicated by the absence of diffraction peaks in the XRD. SEDS sprayedrapamycin has diffraction peaks that are identical to the authenticsample indicating that the two materials are the same. FIG. 9demonstrates particle size control using the SEDS process. In the upperleft is an optical photograph of a view cell containing a substrate(horizontal line in bottom portion of the window) held at 2500 psi. AnSEM micrograph is in the lower left image showing aggregated particlesaveraging approximately 35 nm in size. The upper right panel in FIG. 9shows an optical photograph of a view cell pressurized at 1200 psi. Theparticles are sufficiently large to scatter light as evidenced by thecloud of particles above the substrate in the image. The lower rightpanel in FIG. 9 shows that the particle size is approximately 20microns. FIG. 10 shows the SEDS spraying apparatus with a two-nozzledesign and novel high voltage power supply used for the electrostaticcollection of the SEDS sprayed particles. By operating at voltages belowthe component with the lowest ionization potential, electrostaticcollection of the SEDS sprayed particles can be achieved.

Example 2 General Spray Coating 1

A solution containing a therapeutic chemical compound that is saturatedin a solvent or supersaturated in a solvent is sprayed at a flow ratesufficient to achieve flow into a chamber of known volume pressurizedabove ambient pressure and containing a medical device substrate. Thesystem temperature is held constant or allowed to vary so that anynumber of points in the phase diagrams of the solution or mixture or anyof its individual components can be mapped in pressure—temperature,volume-pressure or pressure-volume space constituting liquid, gas orsupercritical CO₂ conditions. CO₂ in any single phase or combination ofphases flows through the chamber at a mass flow rate of 5 gm/min to somemultiple of this flow rate. After a period of time ranging from secondsto minutes or hours have elapsed, the solute and solvent flow that is asolution of the therapeutic compound and suitable solvent for the chosensolute or solutes cease but CO₂ flow continues for an additional periodof time maintaining constant pressure during this period. After thistime period, the pressure is dropped to atmospheric pressure. During thespray coating process the particles are attracted to the medicalsubstrate by charging the substrate oppositely to that of the sprayedparticle charge by applying a voltage that is greater than 5000 V butless than the ionization potential of the most easily ionized componentof the mixture. The particles may also traverse an electromagnetic fieldsuch that the field is used to guide the particle to a target.

Example 3 Spray Coating 2

A solution of equal parts of one solvent and another miscible solventcontaining therapeutic chemical compound is prepared so that compound isnot saturated. This solution is sprayed at a known flow rate rangingfrom 1 mL/min to 100 mL/min into a chamber of known volume andpressurized above ambient pressure. The system temperature is maintainedat a constant level or allowed to vary so that any number of points inthe phase diagrams of the solution or mixture or any of its individualcomponents can be mapped in pressure—temperature, volume-pressure orpressure-volume space. CO₂ flows through the chamber at a known flowrate. Spraying is stopped after a period of time, but CO₂ flow continuesfor an additional period of time sufficient to ensure that the chambervolume has been turned over or replaced a sufficient number of times toremove any residual solvent or co-solvent from the chamber after whichthe pressure is reduced to atmospheric pressure. As in the aboveexample, the particles generated in the spray process are collected onthe medical substrate electrostatically as they are generated.

Example 4 Spray Coating 3

A therapeutic compound in a crystalline dry powder state is sprayedthrough a nozzle using dry powder coating process directed toward astent. From a separate nozzle a CO₂ solution containing the polymer anda co-solvent or a polymer solution prepared in a suitable solvent suchas dimethyl ether is sprayed toward the stent. The CO₂ flow rate isvariable. The temperature of the stent and therapeutic chemical compoundremain at room temperature or below room temperature in order to preventdegradation of thermally sensitive therapeutic compounds but the polymersolution temperature is maintained above the solvent criticaltemperature and pressure so that a supercritical solution or nearsupercritical solution exists. The particles are electrostaticallycaptured during their generation or as they exit the dry powder spraynozzle as described in the previous examples.

Example 5 Uniform Surface Coating

The ability to uniformly coat arterial stents with controlledcomposition and thickness using electrostatic capture in a rapidexpansion of supercritical solution (RESS) experimental series has beendemonstrated. This technique involves spraying an equal part mixture ofthe therapeutic compound such as rapamycin and polymers such as PBMA andPEVA using a spray coating and collection technique described herein. Todetermine coating composition, infrared spectroscopy was used to collectthe spectrum of a silicon wafer chip coated simultaneously with anarterial stent (FIG. 4). Unique absorption bands were identified foreach mixture component and band area was used as a metric to determineincorporation of each compound in the coating.

The individual bands used for compositional analysis were determined byspray coating Si wafer chips with each component separately. The coatingthickness was determined gravimetrically and calculated from the densityof the materials. It was assumed that the layer is fully dense. Thethickness can be controlled by varying the spray time. In the as sprayedstate, the coating lacks strong adhesion to the substrate. Sintering thecoated substrate (see FIG. 5) dramatically improves coating adhesionwhile leaving the components unaltered as the infrared spectra shown inFIG. 6 confirm. The coating is sintered in a supercritical carbondioxide environment allowing mild sintering conditions to be used withtemperature below 80° C.

Example 6 Spray Coating of Crystalline Rapamycin

Several carbon dioxide based spray-coating methods were attempted tospray deposit rapamycin in crystalline form including RESS withoutsuccessfully controlling rapamycin morphology. One SEDS coating methodwas successful in spray coating crystalline rapamycin as shown in FIGS.7 and 8. A solution of 10 parts hexane and 9 parts THF saturated withRapamycin is sprayed at a flow rate of 0.5 mL/min into a 25 mL chamberpressurized at 82 bar with carbon dioxide. The system temperature isheld constant at 25° C. constituting liquid CO₂ conditions. CO₂ flowsthrough the pressurized chamber at a mass flow rate of 5 gm/min. After 5minutes have elapsed, the drug and polymer spray cease but CO₂ flowcontinues for an additional 20 minutes maintaining constant pressureduring this period. After this time period, the pressure is dropped toatmospheric pressure. The particles are attracted to the substrate bycharging the substrate oppositely to the particle charge by applying avoltage that is greater than 5000 V but less than the ionizationpotential of the most easily ionized component of the mixture.

As the SEM images show in FIG. 7, crystalline rapamycin was deposited onthe substrate and the crystal size is approximately 2 microns (rightpanel in the figure) along its major axis with large crystallineaggregates distributed across the substrate surface (left panel).

The diffraction peaks in the XRD shown in FIG. 8 confirm the identity ofthe crystals as rapamycin since the sprayed rapamycin (lowest spectrum)matches the as received rapamycin (middle spectrum) peak for peak. XRDresults for other failed attempts (upper spectrum) to spray crystallinerapamycin are included for comparative purposes. The amorphousdiffraction pattern displayed in the top trace of FIG. 8 was obtainedfrom a RESS sprayed sample and is also representative of failed attemptsto spray crystalline rapamycin using SEDS based approaches using onlypolar or non-polar solvents. The goal of this experimental series was todemonstrate a carbon dioxide technique that could spray rapamycin incrystalline form. No attempt was made to control crystal size, coverageuniformity, or aggregation

Example 7 Particle Size Control

FIG. 9 shows optical and electron microscope comparison of the SEDSspraying process under different pressure conditions. FIG. 9( a) showsan optical photograph taken of the view cell with CO₂ present at 1200psi and 25° C. The nozzle appears as an angled line at approximately 11o'clock originating from the left of the view cell. The substrateappears as a horizontal line in the bottom of the view cell. FIG. 9( c)is a scanning electron micrograph of the particles deposited on thesubstrate that was removed from the view cell in 9(a). The scale of thescanning electron micrograph demonstrates the particle size.

FIG. 9( b) shows an optical photograph taken of the view cell with CO₂present at 2500 psi and 25° C. The nozzle appears as an angled line atapproximately 11 o'clock originating from the left of the view cell. Thesubstrate appears as a horizontal line in the bottom of the view cell.FIG. 9( d) is a scanning electron micrograph of the particles depositedon the substrate that was removed from the view cell in 9(b). The scaleof the scanning electron micrograph demonstrates the particle size.These images demonstrate an ability to control particle size andmorphology. Both these features are important as elution rates can beaffected by both parameters.

Example 8 Further Process Equipment

Further equipment is shown in FIG. 10. This apparatus is used to sprayrapaymycin in crystalline form using a SEDS process with electrostaticcapture. The unique features of this apparatus are the dual nozzledesign and high voltage pass through permitting electrostatic capture ofthe sprayed particles. In other respects the design is similar to otherSEDS equipment.

The dual nozzle separates polymer and drug spraying from each otherwhich is important as it has been shown that polymers co-sprayed withanother component can influence the ability of non polymer component toform particulate in the desired morphology. However, both the componentsare sprayed into the same chamber allowing the particles to be collectedat a single point.

The high voltage pass through permits electrostatic capture of thesprayed components onto the desired substrate.

Example 9 Preparation Of Supercritical Solution Comprising,polyethylene-co-vinyl acetate (PEVA) and polybutyl methacrylate (PBMA)in isobutylene

75 mg of PEVA and 75 mg of PBMA are placed in a 25 mL view cell. Theview cell is heated to 150° C.

Isobutylene is added to a pressure of 3000 psig. Under these conditions,a clear solution is produced.

Example 10 Preparation of Supercritical Solution Comprisingpolyethylene-co-vinyl acetate (PEVA) and polybutyl methacrylate (PBMA)in isobutylene

150 mg of PEVA and 150 mg of PBMA are placed in a 25 mL view cell. Theview cell is heated to 150° C.

Isobutylene is added to a pressure of 4000 psig. Under these conditions,a clear solution is produced.

Example 11 Preparation of Supercritical Solution Comprisingpolyethylene-co-vinyl acetate (PEVA) and polybutyl methacrylate (PBMA)in isobutylene and CO₂

75 mg of PEVA and 75 mg of PBMA are placed in a 25 mL view cell and thecell is heated to 150° C.

Isobutylene is added to a pressure of 4000 psig, to produce a clearsolution. (v/v %) CO₂ is added. The addition of CO₂ at this volumepercent does not precipitate the dissolved polymer.

Example 12 Preparation of Supercritical Solution Comprisingpolyethylene-co-vinyl acetate (PEVA) and polybutyl methacrylate (PBMA)in isobutylene and CO₂.

150 mg of PEVA and 150 mg of PBMA are placed in a 25 mL view cell andthe cell is heated to 150° C.

Isobutylene is added to a pressure of 4000 psig, to produce a clearsolution. (v/v %) CO₂ is added. The addition of CO₂ at this volumepercent does not precipitate the dissolved polymer; however addition ofCO₂ at higher volume fraction leads to polymer precipitation, underthese conditions.

Example 13 Dry Powder Rapamycin Coating on an Electrically Charged 316Stainless Steel Coupon

A 1 cm×2 cm stainless steel metal coupon serving as a target substratefor rapamycin coating was placed in a vessel and attached to a highvoltage electrode. The vessel (V), of approximately 1500 cm³ volume, wasequipped with two separate nozzles through which rapamycin or polymerscould be selectively introduced into the vessel. Both nozzles weregrounded. Additionally, the vessel (V) was equipped with a separate portwas available for purging the vessel. Upstream of one nozzle (D) was asmall pressure vessel (PV) approximately 5 cm³ in volume with threeports to be used as inlets and outlets. Each port was equipped with avalve which could be actuated opened or closed. One port, port (1) usedas an inlet, was an addition port for the dry powdered rapamycin. Port(2), also an inlet was used to feed pressurized gas, liquid, orsupercritical fluid into PV. Port (3), used as an outlet, was used toconnect the pressure vessel (PV) with nozzle (D) contained in theprimary vessel (V) with the target coupon. Dry powdered Rapamycinobtained from LC Laboratories in a predominantly crystalline solidstate, 50 mg milled to an average particle size of approximately 3microns, was loaded into (PV) through port (1) then port (1) wasactuated to the closed position. Gaseous carbon dioxide was then addedto (PV) to a pressure of 400 to 600 psig at 20° C. through port (2),then port (2) was closed to the source gas. The metal coupon was thencharged to 40 kV using a Glassman Series EL high-voltage power source.Port (3) was then actuated open allowing for the expansion of thepressurized carbon dioxide and rapamycin powder into the vessel (V)while the coupon remained charged. After approximately 60-seconds thevoltage was eliminated and the coupon was isolated. Upon visualinspection of the coupon using an optical microscope it was determinedthat the entire surface area of the coupon, other than a small portionmasked by the voltage lead, was covered in a relatively evendistribution of powdered material. X-ray diffraction (XRD) confirmedthat the powdered material was largely crystalline in nature asdeposited on the metal coupon. UV-Vis and FTIR spectroscopy confirmedthat the material deposited on the coupon was rapamycin.

Example 14 Dry Powder Rapamycin Coating on a 316-Stainless Steel Couponwith No Electrical Charge

A coupon was coated in an identical fashion to what was described inExample 13. However, no voltage was applied to the coupon throughout thedry powder-coating run. After expansion of the carbon dioxide and thepowdered rapamycin into vessel (V), and a period of roughly 60 seconds,the coupon was isolated and evaluated. The coupon was analyzed using anoptical microscope and showed some dry powder material on much of thesurface of the coupon. However, the coverage of drug on the surface wasmuch lower than in example 1 and there was notably more variability incoverage at different locations on the coupon surface. The total powdercoating was estimated to be about ⅓rd the amount determined to becrystalline rapamycin in example 1.

Example 15 Polymer Coating on an Electrically Charged 316-StainlessSteel Coupon Using Rapid Expansion from a Liquefied Gas

A coating apparatus as described in example 13 above was used in theforegoing example. In this example the second nozzle, nozzle (P), wasused to feed precipitated polymer particles into vessel (V) to coat a316-stainless steel coupon. Nozzle (P) was equipped with a heater andcontroller to minimize heat loss due to the expansion of liquefiedgases. Upstream of nozzle (P) was a pressure vessel, (PV2), withapproximately 25-cm³ internal volume. The pressure vessel (PV2) wasequipped with multiple ports to be used for inlets, outlets,thermocouples, and pressure transducers. Additionally, (PV2) wasequipped with a heater and a temperature controller. Each port wasconnected to the appropriate valves, metering valves, pressureregulators, or plugs to ensure adequate control of material into and outof the pressure vessel (PV2). One outlet from (PV2) was connected to ametering valve through pressure rated tubing which was then connected tonozzle (P) located in vessel (V). In the experiment, 75 mg ofpolyethylene-co-vinyl acetate (PEVA) obtained from Aldrich ChemicalCompany with approximately 33-weight percent vinyl acetate and 75 mg ofpoly(butyl methacrylate) (PBMA) also obtained from Aldrich ChemicalCompany were added to pressure vessel (PV2). Dichlorofluoromethane, 20.0grams, was added to the pressure vessel (PV2) through a valve and inlet.Pressure vessel (PV2) was then heated to 40° C. bringing the pressureinside the isolated vessel to approximately 40 psig. Nozzle (P) washeated to 120° C. After sufficient time to dissolve the two polymers inthe liquefied gas inside (PV2), the vessel (PV2) was over-pressurizedwith helium to approximately 200 psig using a source helium tank and adual stage pressure regulator. See U.S. Pat. No. 6,905,555 for adescription of Helium displacement art. A 1-cm×2-cm 316-stainless steelcoupon was placed into vessel (V) and attached to an electrical lead.Nozzle (P) was attached to ground. The coupon was charged to 40 kV usinga Glassman high-voltage power source at which point the metering valvewas opened between (PV2) and nozzle (P) in pressure vessel (PV). Polymerdissolved in liquefied gas and over-pressurized with helium to 200 psigwas fed at a constant pressure of 200 psig into vessel (V) maintained atatmospheric pressure through nozzle (P) at an approximate rate of 3.0cm³/min. After approximately 5 seconds, the metering valve was closeddiscontinuing the polymer-solvent feed. Vessel (V) was purged withgaseous CO₂ for 30 seconds to displace chlorofluorcarbon. Afterapproximately 30 seconds, the metering valve was again opened for aperiod of approximately 5 seconds and then closed. This cycle wasrepeated about 4 times. After an additional 1-minute the applied voltageto the coupon was discontinued and the coupon was removed from pressurevessel (V). Upon inspection by optical microscope, a polymer coating wasevident as evenly distributed on all non-masked surfaces of the coupon.Dissolution of the polymer mixture from the surface of the couponfollowed by quantification using standardized quantitative FT-IR methodsdetermined a composition of approximately 1:1 PEVA to PBMA on thecoupon.

Example 16 Dual Coating of a Metal Coupon with Crystalline Rapamycin,and 1:1 Mixture of polyethylene-co-vinyl acetate (PEVA) and poly(butylmethacrylate) (PBMA)

An apparatus described in example 13 and further described in example 15was used in the foregoing example. In preparation for the coatingexperiment, 25 mg of crystalline powdered rapamycin with an averageparticle size of 3-microns was added to (PV) through port (1), then port(1) was closed. Then, (PV) was pressurized to 400-600 psig with gaseouscarbon dioxide at 20° C. through port (2), prior to closing port (2).Next, 75 mg of polyethylene-co-vinyl acetate (PEVA) with approximately33-weight percent vinyl acetate and 75 mg of poly(butyl methacrylate)(PBMA) were added to pressure vessel (PV2). Dichlorofluoromethane, 20.0grams, was added to the pressure vessel (PV2) through a valve and inlet.Pressure vessel (PV2) was then heated to 40° C. bringing the pressureinside the isolated vessel (PV2) to approximately 40 psig. Nozzle (P)was heated to 120° C. After sufficient time to dissolve the two polymersin the liquefied gas, the vessel was over-pressurized with helium toapproximately 200 psig using a source helium tank and a dual stagepressure regulator. A 1-cm×2-cm 316-stainless steel coupon was added tovessel (V) and connected to a high-voltage power lead. Both nozzles (D)and (P) were grounded. To begin, the coupon was charged to 40 kV afterwhich port (3) connecting (PV) containing rapamycin to nozzle (D) wasopened allowing expansion of carbon dioxide and ejection of rapamycininto vessel (V) maintained at ambient pressure. After closing port (3)and approximately 60-seconds, the metering valve connecting (PV2) withnozzle (P) inside vessel (V) was opened allowing for expansion ofliquefied gas to a gas phase and introduction of precipitated polymerparticles into vessel (V) while maintaining vessel (V) at ambientpressure. After approximately 5-seconds at a feed rate of approximately3 cm³/min., the metering valve was closed while the coupon remainedcharged. Port (1) was then opened and an additional 25-mg of powderedcrystalline rapamycin was added to (PV), and then port (1) was closed.Pressure vessel (PV) was then pressurized with liquid carbon dioxide to400-600 psig through port (2), after which port (2) was again closed.Maintaining the coupon at an applied voltage of 40 kV, port (3) wasagain opened to nozzle (D) allowing for the expansion of carbon dioxideto a gas and the ejection of the powdered crystalline drug into thevessel (V). After and additional 60-seconds, the metering valve between(PV2) and nozzle (P) was again opened allowing for the expansion of theliquefied solvent to a gas into vessel (V) and the precipitation ofpolymer particles also in vessel (V). The sequential addition of drugfollowed by polymer or polymer followed by drug as described above wasrepeated for a total of four (4) cycles after which the appliedpotential was removed from the coupon and the coupon was removed fromthe vessel. The coupon was then examined using an optical microscope. Aconsistent coating was visible on all surfaces of the coupon exceptwhere the coupon was masked by the electrical lead. The coating appearedconformal but opaque and somewhat granular at high magnification.

Example 17 Dual Coating of a Metal Coupon with crystalline rapamycin,and 1:1 mixture of polyethylene-co-vinyl acetate (PEVA) and poly(butylmethacrylate) (PBMA) followed by Supercritical Carbon Dioxide Annealingor Gaseous Carbon Dioxide Annealing

After inspection of the coupon created in example 16, the coated couponwas carefully placed in a pressure vessel that was pressurized withcarbon dioxide to a pressure of 4500 psig and at a temperature of 60° C.This CO₂ sintering process was done to enhance the physical propertiesof the film on the coupon. The coupon remained in the vessel under theseconditions for approximately 3 hours after which the supercritical CO₂was slowly vented from the pressure vessel and then the coupon wasremoved and reexamined under an optical microscope. The coating wasobserved to be conformal, consistent, and semi-transparent as opposed tothe opaque coating observed and reported in example 16 without densecarbon dioxide treatment. The coated coupon was then submitted for x-raydiffraction (XRD) analysis which confirmed the presence of crystallinerapamycin in the polymer matrix.

Example 18 Dual Coating of a Metal Cardiovascular Stent with crystallinerapamycin, and 1:1 mixture of polyethylene-co-vinyl acetate (PEVA) andpoly(butyl methacrylate) (PBMA)

The apparatus described in examples 13, 15, and 16 above was used in theforegoing example. The metal stent used was a Tristar™ Coronary Stent ofa nominal size of 3 mm by 13 mm. The stent was coated in an identicalfashion to the coupon described in example 16 above. The stent wascoated in an alternating fashion whereby the first coating layer of drugwas followed by a thin layer of polymer. These two steps, called adrug/polymer cycle, were repeated 3-times so that the last appliedcoating layer was polymer. After completion of the coating step, thestent was removed from the vessel (V) and placed in a small pressurevessel where it was exposed to supercritical CO₂ as described above inexample 16. After this low temperature annealing step, the stent wasremoved and examined using an optical microscope. The stent was thenanalyzed using a scanning electron microscope (SEM) equipped with a fastion bombarding (FIB) device to provide cross-sectional analysis of thecoated stent. The SEM micrograph at multiple locations on the stentindicated a completely conformal coating of between 6 and 15-microns inthickness. Evidence of rapamycin crystallites was also apparent in themicrographs.

Example 19 Layered Coating of a Cardiovascular Stent with anAnti-Restenosis Therapeutic and Polymer in Layers to Control DrugElution Characteristics

A cardiovascular stent is coated using the methods described in examples17 and 18 above. The stent is coated in such as way that the drug andpolymer are in alternating layers. The first application to the barestent is a thin layer of a non-resorbing polymer, approximately2-microns thick. The second layer is a therapeutic agent withanti-restenosis indication. Approximately 35 micrograms are added inthis second layer. A third layer of polymer is added at approximately2-microns thick, followed by a fourth drug layer which is composed ofabout 25 micrograms of the anti-restenosis agent. A fifth polymer layer,approximately 1-micron thick is added to stent, followed by the sixthlayer that includes the therapeutic agent of approximately15-micrograms. Finally, a last polymer layer is added to a thickness ofabout 2-microns. After the coating procedure, the stent is annealedusing carbon dioxide as described in example 16 above. In this example adrug eluting stent (DES) is described with low initial drug “burst”properties by virtue of a “sequestered drug layering” process, notpossible in conventional solvent-based coating processes. Additionally,by virtue of a higher concentration of drug at the stent ‘inter-layer’the elution profile is expected to reach as sustained therapeuticrelease over a longer period of time.

Example 20 Layered Coating of a Cardiovascular Stent with anAnti-Restenosis Therapeutic and an Anti-Thrombotic Therapeutic in aPolymer Matrix

A cardiovascular stent is coated as described in example 19 above. Inthis example, after a first polymer layer of approximately 2-micronsthick, a drug with anti-thrombotic indication is added in a layer ofless than 2-microns in thickness. A third layer consisting of thenon-resorbing polymer is added to a thickness of about 4-microns. Nextanother drug layer is added, a different therapeutic, with ananti-restenosis indication. This layer contains approximately 100micrograms of the anti-restenosis agent. Finally, a polymer layerapproximately 2-microns in thickness is added to the stent. Aftercoating the stent is treated as described in example 16 to anneal thecoating using carbon dioxide.

Example 22 Coating of Stents with Rapamycin, polyethylene-co-vinylacetate (PEVA) and polybutyl methacrylate (PBMA)

Micronized Rapamycin was purchased from LC Laboratories. PBMA (Mw=˜237k)and PEVA (33% vinyl acetate content) were purchased from AldrichChemicals. Two kinds of stents were used: 3 mm TriStar® from Guidant and6 cell× 8-mm, BX Velocity® from Cordis. The stents were coated by dryelectrostatic capture followed by supercritical fluid sintering, using 3stents/coating run and 3 runs/data set. The coating apparatus isrepresented in FIG. 12. Analysis of the coated stents was performed bymultiple techniques on both stents and coupons with relevant controlexperiments.

In this example a 1:1 ratio of PEVA and PBMA is dissolved in aDichlorofluoromethane (CCl₂FH), which is a compressed gas solvent knownto be in the class of “Freon” chemicals. The physical properties of thisparticular Freon are as follows:

BP=8.9 C Tc=178.33 C

Pc=751.47 psigDc=0.526014 g/cc

A solution was formed by mixing 30 mg of the combined polymers per gramdichlorofluoromethane. The solution was then maintained at 60° C. atvapor pressure (approx 28 psig) until the solution was ready to spray.The solution was then pressurized by adding an immiscible gas to the topof the vessel—typically Helium. Adding Helium compressed theFreon+polymer solution up to 700 (+/−50 psig), which resulted in acompressed fluid. The polymer+Freon solution was then pushed through anozzle having an inner diameter of 0.005″ by continuous addition ofHelium into the vessel. The solvent (dichlorofluoromethane) is rapidlyvaporized coming out of the nozzle (which is heated to 120° C.),as it'sboiling point is significantly below room temperature.

The Drug is deposited by dry powder spray coating. Between 10-30 mg ofdrug are charged into a small volume of tubing, which is thenpressurized with gaseous CO₂ to 400 psig. The mixture flows through anozzle having an inner diameter of 0.187″ into the coating vessel wherethe stents are held. During electrostatic deposition, the stent ischarged and the nozzles are grounded. FIGS. 12 and 13 show the apparatusused for the coating and sintering process.

Example 23 Optical Microscopy Analysis of Rapamycin/PEVA/PBM CoatedStents

The stents produced in example 22 were examined by optical microscopy,at 40× magnification with back and side lighting. This method was usedto provide a coarse qualitative representation of coating uniformity andto generally demonstrate the utility of the low-temperature CO₂annealing step. The resulting photos shown in FIG. 14, demonstrate thedifferences in appearance (a) before and (b) after annealing in densecarbon dioxide at 40° C. Photos of the outside, edge and inside surfacesare presented in FIG. 15 (a), prior to sintering, which clearly showsnanoparticle deposition equally on all surfaces of the stent, and 15 (b)after sintering, with the film showing a smooth and opticallytransparent polymer. FIG. 16 shows additional 40× magnified images ofRapamycin/PEVA/PBMA coated stents, showing the outside and insidesurfaces, (a) before sintering, further demonstrating the nanoparticledeposition equally on all surfaces of the stent and (b) after sintering,showing a smooth and optically transparent polymer film. FIG. 17 shows a100× magnified mages of Rapamycin/PEVA/PBMA Coated Stents. Crystallinedrug is clearly visible embedded within a highly uniform polymercoating.

Example 24 Scanning Electron Microscopy Analysis of Rapamycin/PEVA/PBMCoated Stents

The stents produced in example 21 were examined by scanning electronmicroscopy, and the resulting images presented in FIG. 18 at (a) ×30magnification, (b) ×250 magnification, (c) ×1000 magnification and (d)×3000 magnification. Clearly the nanoparticles have been sintered to aneven and conformal film, with a surface topology of less than 5 microns,and demonstrate clear evidence of embedded crystalline rapamycin.Cross-sectional (FIB) images were also acquired and are shown in FIG.19( a) at 7000× and (b) 20000× magnification. An even coating ofconsistent thickness is visible. Four cross-sectional thicknesses weremeasured: (1) 10.355 μM, (2) 10.412 μM, (3) 10.043 μM and (4) 10.157 μM,to give an average thickness of 10.242 μM, with only 2% (±0.2 μM)variation.

Example 25 Differential Scanning Calorimetry (DSC) of Rapamycin/PEVA/PBMCoated Stents

The stents produced in example 21 were examined by Differential ScanningCalorimetry (DSC). Control analyses of PEVA only, PBMA only andRapamycin only are shown in FIG. 20 (a), (b) and (c) respectively. TheDSC of the Rapamycin, PEVA and PBMA coated stent is shown in FIG. 20(d). The rapamycin crystalline melt is clearly visible at 185-200° C.and distinct from those of the polymers.

Example 26 X-Ray Diffraction (XRD) of Rapamycin/PEVA/PBM Coated Stents

The stents produced in example 21 were examined by X-Ray Diffraction(XRD). The control spectrum of micro-ionized Rapamycin powder is shownin FIG. 21 (a). The XRD of the Rapamycin, PEVA and PBMA coated, sinteredstent is shown in FIG. 21 (b), showing that the Rapamycin remainscrystalline (˜64%) throughout the coating and sintering process.

Example 27 Confocal Raman Analysis of Rapamycin/PEVA/PBM Coated Stents

The stents produced in example 21 were examined by Confocal RamanAnalysis, to provide depth profiling from the coating surface down tothe metal stent. FIG. 22 (a) shows the Rapamycin depth profile outsidecircumference (Rapamycin peak at ˜1620) and 22 (b) shows the polymerdepth profile outside circumference, clearly demonstrating that the drugis distributed throughout polymer coated stents. The highest drugcontent appears in the center of the polymer coating (˜4 μM from the airsurface), which is controllable, via the coating and sinteringconditions used. In certain embodiments of the invention, the drug wouldbe close to the air surface of the coating. In other embodiments, thedrug would be closer to the metal stent. In other embodiments, more thanone drug would be deposited in the coating, wherein one drug would becloser to the air surface and another drug would be closer to the metalsurface. In yet other embodiments, the drugs would be distributedtogether throughout the coating.

Example 28 UV-Vis and FT-IR Analysis of Rapamycin/PEVA/PBM Coated Stentsfor Quantification of Coating Components

A UV-VIS method was developed and used to quantitatively determine themass of rapamycin coated onto the stents with poly(ethylene-co-vinylacetate) (PEVA) and poly(butyl methacrylate) (PBMA). The UV-Vis spectrumof Rapamycin is shown in FIG. 23 (a) and a Rapamycin calibration curvewas obtained, λ@ 277 nm in ethanol, as shown in FIG. 23 (b). Rapamycinwas dissolved from the coated stent in ethanol, and the drugconcentration and mass calculated. An average mass of 74±11 μg Rapamycinwas loaded onto the stents. The results in FIG. 24 (a) show a consistentdrug coating: (+/−) 15% stent-to-stent, (+/−) 12% run-to-run, (meanconcentrations (3 stents each); 4 cell by 8 mm parylene coated).

An FT-IR method was developed and used to quantitatively determine themass of PEVA and PBMA coated onto stents with rapamycin. The FT-IRspectra of PEVA and PBMA is shown in FIG. 23 (c) and calibration curveswere obtained using Beer's Law for PEVA λ@ ˜1050 cm⁻¹ and PBMA λ@ ˜1285cm⁻¹, as shown in FIGS. 23 (d) and (e), respectively. The polymers weredissolved from the coated stent in methylene chloride, and the polymerconcentrations and the masses calculated accordingly. An average mass of1060±190 μg PEVA and 1110±198 μg PBMA was loaded onto the stents. Theresults in FIGS. 24 (b) and (c) show a consistent polymer coating: (+/−)18% stent-to-stent, (+/−) 15% run-to-run, (mean concentrations (3 stentseach); 4 cell by 8 mm parylene coated).

Example 29 Coating of Stents with Paclitaxel/PEVA/PMBA

3 mm Guidant TriStar® Stents were coated with a Paclitaxel/PEVA/PMBAcomposite, by processes of the invention, as described herein. Thecoated stents were examined by optical microscopy, and photos of theoutside surface of the stent (a) prior to sintering and (b) aftersintering are shown in FIG. 25. FIG. 26 (a) represents the UV-Viscalibration curve developed for Paclitaxel, λ@ 228 nm in ethanol, usingthe methods of example 28, as described above. Rapamycin was dissolvedfrom the coated stent in ethanol, and the drug concentration and masscalculated, to give an average mass of 148±14 μg loaded Rapamycin, asshown in FIG. 26 (b).

Example 30 UV-Vis and FT-IR Analysis of Rapamycin/PEVA/PBM Coated Stentsfor Quantification of Coating Components

The UV-VIS and FT-IR methods, described in example 28, were used todetermine the quantities of Rapamycin, PEVA and PBMA respectively, fromstents coated with Rapamycin, PEVA and PBMA by processes of theinvention, as described herein. The component quantifications are shownin FIG. 27 and calculated; (a) an average mass of 81±3 μg Rapamycin wasloaded onto the stents, (b) an average mass of 391±69 μg PEVA and (c)268±64 μg PBMA was loaded onto the stents.

Example 31 Coating of Stents with Rapamycin or Paclitaxel,polyethylene-co-vinyl acetate (PEVA) and polybutyl methacrylate (PBMA)

A 25 mL stainless steel reservoir is charged with 150.0±0.1 mg ofpoly(ethylene co-vinyl acetate) (PEVA) and 150.0±0.1 mg of poly(butylmethacrylate) (PBMA) to which is transferred 20.0±0.3 grams ofdichlorofluoromethane. The pressure rises in the reservoir toapproximately 28 psig. The reservoir is heated to 60° C. aftertransferring dichlorofluoromethane to the reservoir. The reservoir isthen pressurized with helium until the pressure reaches 700±30 psig.Helium acts as a piston to push out the dichlorofluoromethane-polymersolution. The reservoir is isolated from the system by appropriatevalving. A second stainless steel reservoir with volume of 15±1 mL ischarged with 13 mg of drug compound (rapamycin or Paclitaxel). Thisreservoir is pressurized to 400±5 psig with carbon dioxide gas. Thetemperature of the drug reservoir is room temperature. The reservoir isisolated from the system by appropriate valving.mA third reservoir ischarged with tetrahydrofuran or dichloromethane solvent so that thepolymer nozzle can be flushed between polymer sprays. This reservoir isalso pressurized with helium to 700 psig and isolated from the system byappropriate valving. The polymer spray nozzle is heated to 120±2° C.while the drug spray nozzle remains at room temperature. Stents areloaded into the stent fixture and attached to a high voltage source viaan alligator clamp. The alligator clamp enters the coating chamber viaan electrically insulated pass through. Carbon dioxide gas is admittedinto the coating vessel at 8 psig for a period of 5 minutes through athird gas flush nozzle to remove air and moisture to eliminate arcingbetween the nozzles and components held at high potential. Afterflushing the coating chamber with carbon dioxide gas, a potential of 35kV is applied to the stents via a high voltage generator. This potentialis maintained during each coating step of polymer and drug. Thepotential is removed when the polymer spray nozzle is flushed withtetrahydrofuran or dichloromethane. Polymer solution is sprayed for 7secs from the polymer solution reservoir into the coating chamber. Theapplied potential is turned off and the polymer nozzle is removed fromthe coating chamber and flushed with solvent for 2 minutes and thenflushed with helium gas for approximately one minute until all solventis removed from the nozzle. The coating chamber is flushed with carbondioxide gas during the nozzle solvent flush to flush outdichlorofluoromethane gas. The polymer spray nozzle is placed back inthe coating chamber and the carbon dioxide gas flush is stopped. A 35 kVpotential is applied to the stents and the drug compound is rapidlysprayed into the coating chamber by opening appropriate valving. Afterone minute of rest time, polymer spray commences for another sevenseconds. The process can be repeated with any number of cycles.

The various analytical methods developed to examine the coated stentsand the results they generated are summarized in the table below:

Analytical Method To Provide Result Optical Visible images of thestents. Nanoparticles deposited evenly microscope Empirical survey ofcoating uniformity on all surfaces of stent Sintering to conformal film(with visual evidence of crystalline drug) SEM Top-down andcross-sectional images Very smooth and conformal films (electronmicrographs) at various at high magnification magnifications. 10.2 ± 0.3μm well-sintered films Gross estimates of coating uniformity viacross-sectional analysis and thickness X-ray diffraction Quantitativeindication of drug +65% crystalline rapamycin on (XRD) morphology incoated films on proxy proxy samples substrates Differential Qualitativeevidence of crystalline Demonstrated rapamycin Scanning rapamycin fromproxy substrates crystalline melt (185-200° C.) Calorimetry (crystallinemelt) (DSC) Confocal Raman Compositional data (drug, polymer A, Drugdistributed throughout Polymer B) at various depths in the film polymercoated stents on the coated stents (i.e. surface, 2 μm deep, 4-μm deep,etc.) UV-Vis Quantitative compositional information 74 ± 11 μg drugloaded onto Spectroscopy for drug loading on ‘sacrificial’ coatedstents, run-to-run control within stents, BL method 12% deviation FT-IRQuantitative compositional information 1060 ± 190 μg PEVA loaded ontospectroscopy for loading of both polymers on stents ‘sacrificial’ coatedstents, BL method 1110 ± 198 μg PBMA loaded onto stents

Example 32

(FIGS. 29 and 30) An elution medium was identified to produce elutionprofile under static conditions. SDS surfactant at 1% (v/v) in phosphatebuffer at pH 7.0 was selected as the elution medium based uponcomparison of the elution profiles generated with this medium to thedesired elution profiles. The experiment showed that it was possible togenerate an elution profile over a period of 30 hrs in athermostatically controlled bath held at 37±1° C. over the time of theelution experiment (see FIG. 29). The samples used were sterilized atusing an ethylene oxide process. Additional elution work was carried outto develop an elution method. The materials used were supplied byAldrich (polymers) and LC Laboratories (Rapamycin). The elution profileis shown in FIG. 30. Another set of stents was analyzed. The setincluded 6 drug coated stents and two placebo stents. This set of stentsshowed no elution; however, the placebo stent was sinteredsimultaneously with the drug coated stent. Upon analysis, the placeboshowed some rapamycin. These stents were subjected to stripping analysisto determine if any drug was present but simply did not elute. No drugwas found.

Example 33 Mechanical Stability of Illustrative Coated Stents (FIG. 31)

Balloon Inflation: stents were transferred onto a balloon dilationcatheter vial an “over the wire” transfer.

A stylet was inserted into the lumen of the catheter; the stent waspicked up via the sterile needle and transferred onto the stylet. Thestent was manipulated on to the center of the balloon- and the entireassembly was placed under the microscope. Due to the lack of crimpingequipment, the stent was adjusted in position by the use of a smallvascular forceps placed on the balloon to preclude the stent fromshooting off during inflation and balloon expansion.

Inflation/(slow inflation)

The balloon was inflated using an indeflator with an atmosphericpressure gauge- and expanded in the same fashion that one would inflatea balloon/stent during an intervention. (rapid expansion)—and the stentswere observed at the completion of the “procedure”. The balloon wastaken up one atmosphere at a time—and the stent/balloon interfaceexamined under the microscope at each inflation. The balloon stent wasplaced on a clean microscope slide—to catch any particulate. During theentire inflation process—no particulate/no separation/nor flaking wasevidenced on any of the stents. Materials on and around the abluminalarea were seen to be deformed and flattened by the balloon inflation—andwere seen to be in approximation to the stent struts. Any of thematerials that were crossed or jumped from strut to strut wereparticularly examined towards the effect of the expansion on thematerials. In these experiments, the crossed strutted materials wouldbreak off—rather they elongated during the expansion—and never separatedfrom the main body.

Over Inflation

Each of the stents was inflated to its nominal expansion size forexamination—and then the stent was further expanded until balloonrupture—achieving in many cases a 75% increase in size. Particularattention was paid to the inner and outer portions of the angled aspectsof the stent strut that provides the ability to expand. Where thenominal expanded angle might be on the order of 20-25 degrees ofdeflection we were taking the stent to a point where these angles were45 plus degrees. None of the hyper expansion caused any deformation orflaking or separation of the coating.

The materials showed good adhesion properties. The materials did notexhibit any lack of adhesion even with excessive expansion. In the majorareas of stent flex/deformation during balloon inflation—no separationwas seen. No particulate is evidenced in the shipping vials. While somedegree of strut-to-strut “cross talk” was seen—it was primarily as aresult of environmental contamination—which can be eliminated or reduce,for example, by using clean room and laminar flow hoods and/or filteredgases. The polymer and drug combination appears to have excellentelongation properties.

In summary, in certain embodiments, the present invention provides amethod for coating drug-eluting stents. Polymer(s) and drug(s) areapplied in a controlled, low-temperature, solvent-free process. In oneembodiment Rapamycin, PBMA and PEVA are applied to provide a conformal,consistent coating at target Rapamycin loading, in a 1:1 mixture ofPBMA:PEVA, at a thickness of ˜10 μM, containing zero residual solvent.The Rapamycin is deposited in crystalline morphology (+50%). TheRapamycin/PEVA/PBMA film is applied using a method through which thestent is not exposed to solvents in the liquid state, wherein the drugand polymer content is highly controllable, and easily adaptable fordifferent drugs, different (resorbable and permanent) polymers, multipledrugs on a single stent, and provides for a high degree ofstent-to-stent precision. The absence of exposure of the stent totraditional liquid solvents during deposition enables control over drugcontent at variable film depths.

The foregoing is illustrative of the present invention, and is not to beconstrued as limiting thereof. While embodiments of the presentinvention have been shown and described herein, it will be obvious tothose skilled in the art that such embodiments are provided by way ofexample only. Numerous variations, changes, and substitutions will nowoccur to those skilled in the art without departing from the invention.It should be understood that various alternatives to the embodiments ofthe invention described herein may be employed in practicing theinvention. It is intended that the following claims define the scope ofthe invention and that methods and structures within the scope of theseclaims and their equivalents be covered thereby.

1.-33. (canceled)
 34. A coated implantable medical device, comprising: asubstrate; and a coating disposed on said substrate by a coatingprocess, wherein said coating comprises at least one polymer and atleast one pharmaceutical agent in a therapeutically desirablemorphology, wherein the therapeutically desirable morphology of thepharmaceutical agent is not substantially modified during the coatingprocess, and wherein the therapeutically desirable morphology of saidpharmaceutical agent is crystalline or semi-crystalline.
 35. The medicaldevice of claim 34, wherein said coating comprises at least twopharmaceutical agents and/or active biological agents. 36.-196.(canceled)
 197. The medical device of claim 34, wherein said coating hasa thickness of about 1 to about 30 microns
 198. The medical device ofclaim 34, wherein said coating is substantially free of solvent residue.199. The medical device of claim 34, wherein the coating is sintered ata temperature below the phase transition temperature of the polymerwhereby bulk properties and adhesion of the coating to saidpharmaceutical agent are improved without altering the quality of thepharmaceutical agent or the polymer.
 200. The medical device of claim34, wherein said substrate is a biomedical implant selected from thegroup consisting of stents (e.g., vascular stents), electrodes,catheters, leads, implantable pacemaker, cardioverter or defibrillatorhousings, joints, screws, rods, ophthalmic implants, femoral pins, boneplates, grafts, anastomotic devices, perivascular wraps, sutures,staples, shunts for hydrocephalus, dialysis grafts, colostomy bagattachment devices, ear drainage tubes, leads for pace makers andimplantable cardioverters and defibrillators, vertebral disks, bonepins, suture anchors, hemostatic barriers, clamps, screws, plates,clips, vascular implants, tissue adhesives and sealants, tissuescaffolds, various types of dressings (e.g., wound dressings), bonesubstitutes, intraluminal devices, and vascular supports.
 201. Themedical device of claim 34, wherein said substrate further comprises atop layer disposed on said coating wherein said top layer is a polymerfilm.
 202. The medical device of claim 201, wherein said polymer filmhas a thickness of 0.5 to 10 microns.
 203. The medical device of claim34, wherein the substrate is a vascular stent.
 204. The medical deviceof claim 34, wherein the substrate is a coronary stent
 205. The medicaldevice of claim 34, wherein coating covers substantially the entiresurface of said stent
 206. The medical device of claim 34, wherein saidcoating is substantially free of aggregated pharmaceutical agentparticles.
 207. The medical device of claim 34, wherein thepharmaceutical agent is selected form the group consisting ofantirestenotic agents, antidiabetics, analgesics, antiinflammatoryagents, antirheumatics, antihypotensive agents, antihypertensive agents,psychoactive drugs, tranquillizers, antiemetics, muscle relaxants,glucocorticoids, agents for treating ulcerative colitis or Crohn'sdisease, antiallergics, antibiotics, antiepileptics, anticoagulants,antimycotics, antitussives, arteriosclerosis remedies, diuretics,proteins, peptides, enzymes, enzyme inhibitors, gout remedies, hormonesand inhibitors thereof, cardiac glycosides, immunotherapeutic agents andcytokines, laxatives, lipid-lowering agents, migraine remedies, mineralproducts, otologicals, anti parkinson agents, thyroid therapeuticagents, spasmolytics, platelet aggregation inhibitors, vitamins,cytostatics and metastasis inhibitors, phytopharmaceuticals,chemotherapeutic agents and amino acids. Examples of suitable activeingredients are acarbose, antigens, beta-receptor blockers,non-steroidal antiinflammatory drugs {NSAIDs], cardiac glycosides,acetylsalicylic acid, virustatics, aclarubicin, acyclovir, cisplatin,actinomycin, alpha- and beta-sympatomimetics, (dmeprazole, allopurinol,alprostadil, prostaglandins, amantadine, ambroxol, amlodipine,methotrexate, S-aminosalicylic acid amitriptyline, amoxicillin,anastrozole, atenolol, azathioprine, balsalazide, beclomethasone,betahistine, bezafibrate, bicalutamide, diazepam and diazepamderivatives, budesonide, bufexamac, buprenorphine, methadone, calciumsalts, potassium salts, magnesium salts, candesartan, carbamazepine,captopril, cefalosporins, cetirizine, chenodeoxycholic acid,ursodeoxycholic acid, theophylline and theophylline derivatives,trypsins, cimetidine, clarithromycin, clavulanic acid, clindamycin,clobutinol, clonidine, cotrimoxazole, codeine, caffeine, vitamin D andderivatives of vitamin D, colestyramine, cromoglicic acid, coumarin andcoumarin derivatives, cysteine, cytarabine, cyclophosphamide,ciclosporin, cyproterone, cytabarine, dapiprazole, desogestrel,desonide, dihydralazine, diltiazem, ergot alkaloids, dimenhydrinate,dimethyl sulphoxide, dimeticone, domperidone and domperidan derivatives,dopamine, doxazosin, doxorubizin, doxylamine, dapiprazole,benzodiazepines, diclofenac, glycoside antibiotics, desipramine,econazole, ACE inhibitors, enalapril, ephedrine, epinephrine, epoetinand epoetin derivatives, morphinans, calcium antagonists, irinotecan,modafinil, orlistat, peptide antibiotics, phenyloin, riluzoles,risedronate, sildenafil, topiramate, macrolide antibiotics, oestrogenand oestrogen derivatives, progestogen and progestogen derivatives,testosterone and testosterone derivatives, androgen and androgenderivatives, ethenzamide, etofenamate, etofibrate, fenofibrate,etofylline, etoposide, famciclovir, famotidine, felodipine, fenofibrate,fentanyl, fenticonazole, gyrase inhibitors, fluconazole, fludarabine,fluarizine, fluorouracil, fluoxetine, flurbiprofen, ibuprofen,flutamide, fluvastatin, follitropin, formoterol, fosfomicin, furosemide,fusidic acid, gallopamil, ganciclovir, gemfibrozil, gentamicin, ginkgo,Saint John's wort, glibenclamide, urea derivatives as oralantidiabetics, glucagon, glucosamine and glucosamine derivatives,glutathione, glycerol and glycerol derivatives, hypothalamus hormones,goserelin, gyrase inhibitors, guanethidine, halofantrine, haloperidol,heparin and heparin derivatives, hyaluronic acid, hydralazine,hydrochlorothiazide and hydrochlorothiazide derivatives, salicylates,hydroxyzine, idarubicin, ifosfamide, imipramine, indometacin,indoramine, insulin, interferons, iodine and iodine derivatives,isoconazole, isoprenaline, glucitol and glucitol derivatives,itraconazole, ketoconazole, ketoprofen, ketotifen, lacidipine,lansoprazole, levodopa, levomethadone, thyroid hormones, lipoic acid andlipoic acid derivatives, lisinopril, lisuride, lofepramine, lomustine,loperamide, loratadine, maprotiline, mebendazole, mebeverine, meclozine,mefenamic acid, mefloquine, meloxicam, mepindolol, meprobamate,meropenem, mesalazine, mesuximide, metamizole, metformin, methotrexate,methylphenidate, methylprednisolone, metixene, metoclopramide,metoprolol, metronidazole, mianserin, miconazole, minocycline,minoxidil, misoprostol, mitomycin, mizolastine, moexipril, morphine andmorphine derivatives, evening primrose, nalbuphine, naloxone, tilidine,naproxen, narcotine, natamycin, neostigmine, nicergoline, nicethamide,nifedipine, niflumic acid, nimodipine, nimorazole, nimustine,nisoldipine, adrenaline and adrenaline derivatives, norfloxacin,novamine sulfone, noscapine, nystatin, ofloxacin, olanzapine,olsalazine, omeprazole, omoconazole, ondansetron, oxaceprol, oxacillin,oxiconazole, oxymetazoline, pantoprazole, paracetamol, paroxetine,penciclovir, oral penicillins, pentazocine, pentifylline,pentoxifylline, perphenazine, pethidine, plant extracts, phenazone,pheniramine, barbituric acid derivatives, phenylbutazone, phenyloin,pimozide, pindolol, piperazine, piracetam, pirenzepine, piribedil,piroxicam, pramipexole, pravastatin, prazosin, procaine, promazine,propiverine, propranolol, propyphenazone, prostaglandins, protionamide,proxyphylline, quetiapine, quinapril, quinaprilat, ramipril, ranitidine,reproterol, reserpine, ribavirin, rifampicin, risperidone, ritonavir,ropinirole, roxatidine, roxithromycin, ruscogenin, rutoside and rutosidederivatives, sabadilla, salbutamol, salmeterol, scopolamine, selegiline,sertaconazole, sertindole, sertralion, silicates, sildenafil,simvastatin, sitosterol, sotalol, spaglumic acid, sparfloxacin,spectinomycin, spiramycin, spirapril, spironolactone, stavudine,streptomycin, sucralfate, sufentanil, sulbactam, sulphonamides,sulfasalazine, sulpiride, sultamicillin, sultiam, sumatriptan,suxamethonium chloride, tacrine, tacrolimus, taliolol, tamoxifen,taurolidine, tazarotene, temazepam, teniposide, tenoxicam, terazosin,terbinafine, terbutaline, terfenadine, terlipressin, tertatolol,tetracycline, teryzoline, theobromine, theophylline, butizine,thiamazole, phenothiazines, thiotepa, tiagabine, tiapride, propionicacid derivatives, ticlopidine, timolol, timidazole, tioconazole,tioguanine, tioxolone, tiropramide, tizanidine, tolazoline, tolbutamide,tolcapone, tolnaftate, tolperisone, topotecan, torasemide,antioestrogens, tramadol, tramazoline, trandolapril, tranylcypromine,trapidil, trazodone, triamcinolone and triamcinolone derivatives,triamterene, trifluperidol, trifluridine, trimethoprim, trimipramine,tripelennamine, triprolidine, trifosfamide, tromantadine, trometamol,tropalpin, troxerutine, tulobuterol, tyramine, tyrothricin, urapidil,ursodeoxycholic acid, chenodeoxycholic acid, valaciclovir, valproicacid, vancomycin, vecuronium chloride, Viagra, venlafaxine, verapamil,vidarabine, vigabatrin, viloazine, vinblastine, vincamine, vincristine,vindesine, vinorelbine, vinpocetine, viquidil, warfarin, xantinolnicotinate, xipamide, zafirlukast, zalcitabine, zidovudine,zolmitriptan, zolpidem, zoplicone, and zotipine.
 208. The medical deviceof claim 34, wherein said polymer is selected from poly(alkylmethacrylates) such as poly(methyl methacrylate) and poly(butylmethacrylate) (PBMA), polyethylene-co-vinyl acetate (PEVA),Polyethylene, polybutylene and polybutylene copolymers, Polyurethanes,polyanhydrides, Aliphatic polycarbonates, poly(3-hydroxybutyrate) andother poly(hydroxyalkanoate)s, poly(alkyl siloxane)s such asPoly(dimethyl siloxane) (PDMA) and other silicone polymers, aliphaticpolyesters, Polyglycolide (PGA), Polylactide (PLA),Poly(lactide-co-glycolide) (PLGA), Poly(ε-caprolactone) (PCL),Polytetrafluoroethylene, (PTFE) and PTFE copolymers, polystyrene andpolystyrene copolymers, and poly(phosphasones).
 209. The medical deviceof claim 34, wherein said polymer is poly(butyl methacrylate) (PBMA),polyethylene-co-vinyl acetate (PEVA) or a mixture thereof.
 210. Themedical device of claim 34, wherein said substrate is an orthopedicdevice.
 211. The medical device of claim 34, wherein the coating hasimproved bulk properties and adhesion of the coating to said substrateobtained by sintering said coating at a temperature below the phasetransition temperature of the polymer without altering the quality ofsaid pharmaceutical agent.
 212. The medical device of claim 34, whereinsaid coating has substantially uniform thickness and coverssubstantially the entire surface of said substrate. 213.-217. (canceled)218. The medical device of claim 34, wherein said coating comprises atleast two pharmaceutical agents.
 219. The medical device of claim 34,wherein the pharmaceutical agent is in the form of particles having anaverage diameter from 2 nm (0.002 microns) to 3000 nm (3 microns). 220.(canceled)
 221. The medical device of claim 34, wherein saidpharmaceutical agent is at least 50% crystalline.
 222. The medicaldevice of claim 34, wherein said pharmaceutical agent is at least 75%crystalline.
 223. The medical device of claim 34, wherein saidpharmaceutical agent is at least 90% crystalline.
 224. The medicaldevice of claim 34, wherein said pharmaceutical agent is at least 95%crystalline.
 225. The medical device of claim 34, wherein saidpharmaceutical agent is at least 99% crystalline.
 226. The medicaldevice of claim 34, wherein said polymer is a mixture of two or morepolymers.
 227. The medical device of claim 226, wherein said mixture ofpolymers forms a continuous film around particles of rapamycin.
 228. Themedical device of claim 226, wherein said two or more polymers areintimately mixed.
 229. The medical device of claim 226, wherein saidmixture comprises no single polymer domain larger than about 20 nm. 230.The medical device of claim 226, wherein each polymer in said mixturecomprises a discrete phase.
 231. The medical device of claim 230,wherein discrete phases formed by said polymers in said mixture arelarger than about 10 nm.
 232. The medical device of claim 230, whereindiscrete phases formed by said polymers in said mixture are larger thanabout 50 nm.
 233. The medical device of claim 34, wherein saidpharmaceutical agent comprises rapamycin, wherein said substrate is astent, and wherein said medical device provides an elution profilewherein about 10% to about 50% of rapamycin is eluted at week 1 afterthe medical device is implanted in a subject under physiologicalconditions, about 25% to about 75% of rapamycin is eluted at week 2 andabout 50% to about 100% of rapamycin is eluted at week
 4. 234. Themedical device of claim 34, wherein the coating process comprisessintering the coating in a supercritical fluid following depositingparticles of the pharmaceutical agent in dry powder form on thesubstrate, and following depositing particles of the polymer in drypowder form on the substrate.
 235. The medical device of claim 34,wherein the pharmaceutical agent comprises a macrolide immunosuppressive(limus) drug.
 236. The medical device of claim 235, wherein themacrolide immunosuppressive drug comprises one or more of rapamycin,40-O-(2-Hydroxyethyl)rapamycin (everolimus), 40-O-Benzyl-rapamycin,40-O-(4′-Hydroxymethyl)benzyl-rapamycin,40-O-[4′-(1,2-Dihydroxyethyl)]benzyl-rapamycin, 40-O-Allyl-rapamycin,40-O-[3′-(2,2-Dimethyl-1,3-dioxolan-4(S)-yl)-prop-2′-en-1′-yl]-rapamycin,(2′:E,4′S)-40-O-(4′,5′-Dihydroxypent-2′-en-1′-yl)-rapamycin,40-O-(2-Hydroxy)ethoxycar-bonylmethyl-rapamycin,40-O-(3-Hydroxy)propyl-rapamycin, 40-O-(6-Hydroxy)hexyl-rapamycin,40-O-[2-(2-Hydroxy)ethoxy]ethyl-rapamycin,40-O-[(3S)-2,2-Dimethyldioxolan-3-yl]methyl-rapamycin,40-O-[(2S)-2,3-Dihydroxyprop-1-yl]-rapamycin,40-O-(2-Acetoxy)ethyl-rapamycin, 40-O-(2-Nicotinoyloxy)ethyl-rapamycin,40-O-[2-(N-Morpholino)acetoxy]ethyl-rapamycin,40-O-(2-N-Imidazolylacetoxy)ethyl-rapamycin,40-O-[2-(N-Methyl-N′-piperazinyl)acetoxy]ethyl-rapamycin,39-O-Desmethyl-39,40-O,O-ethylene-rapamycin,(26R)-26-Dihydro-40-O-(2-hydroxy)ethyl-rapamycin, 28-O-Methyl-rapamycin,40-O-(2-Aminoethyl)-rapamycin, 40-O-(2-Acetaminoethyl)-rapamycin,40-O-(2-Nicotinamidoethyl)-rapamycin,40-O-(2-(N-Methyl-imidazo-2′-ylcarbethoxamido)ethyl)-rapamycin,40-O-(2-Ethoxycarbonylaminoethyl)-rapamycin,40-O-(2-Tolylsulfonamidoethyl)-rapamycin,40-O-[2-(4′,5′-Dicarboethoxy-1′,2′,3′-triazol-1′-yl)-ethyl]-rapamycin,42-Epi-(tetrazolyl)rapamycin (tacrolimus), and42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin(temsirolimus).